ClausMarsh Products

INSTRUCTIONS FOR USE OF THE MEDICINE International nonproprietary name: Ampicillin/ Sulbactam Ingredients: ampicillin/sulbactam. Active ingredient: each bottle contains ampicillin sodium/sulbactam sodium in a ratio of 500 mg/250 mg or 1000 mg/500 mg. Excipient: Description: white powder and solvent in an ampoule for the preparation of a solution for intramuscular and intravenous injections in a glass bottle, sterile pyrogen preparation. Pharmacotherapeutic group: Beta-lactamase inhibitor and combination drug of a broad-spectrum penicillin antibiotic. ATS code: JO1CR01 Pharmacological properties: Pharmacodynamics: Semi-synthetic broad-spectrum ampicillin, a derivative of 6-aminopenicillic acid, has a bactericidal effect on gram(+) and gram(-) aerobes, as well as anaerobes. Ampicillin has a bactericidal effect due to inhibition of the mucopeptide layer of the microbial cell. Ampicillin is not resistant to the action of β-lactamases, therefore it is broken down by some microbes that secrete β-lactamases and loses its effect. Sulbactam does not have a bactericidal effect, inhibits the enzyme β-lactamase and enhances the effect of ampicillin on resistant strains. Ampicillin/sulbactam in vitro β-lactamase-secreting and non-secreting Staphylococcus aureus, Staphylococcus faecalis, Streptococcus pneumoniae, Streptococcus pyogenes, Streptococcus viridans, Haemophilus influenzae, Haemophilus parainfluenzae, Neisseria meningitidis, Branhamella catarrhalis, Escherichia coli, K lebsiella s. , Neisseria gonorrhoeae, Proteus vulgaris, Providencia rettgeri, Providencia stuartii, Morganella morgani, Citobacter spp. Enterobacter spp., Clostridium spp., non-spore-forming anaerobes, for example, has a high bactericidal effect against microorganisms such as Peptococcus spp., Bacteroides spp., as well as Bacteroides fragilis. Gram-positive bacteria that secrete penicillinase are resistant to ampicillin/sulbactam. Pharmacokinetics: Penetrates into most tissues and body fluids; With inflammation, the permeability of the cerebrospinal fluid to the cerebrospinal fluid increases. Ampicillin and sulbactam accumulate in the blood in high concentrations after intravenous and intravenous administration. 28% of ampicillin and 38% of sulbactam are bound to blood proteins. T1/2 is 1 hour. 70-80% is excreted unchanged by the kidneys, as well as with bile and breast milk. Sulbactam undergoes almost no metabolic changes, is excreted by the kidneys and only 25% in the form of metabolites. ndications for use: - In the treatment of diseases caused by microorganisms sensitive to ampicillin/sulbactam: - infections of the skin and soft tissues (staphylo-streptoderma); - infections of the bones and musculoskeletal system; - Intra-abdominal infections (cholecystitis, pancreatitis, etc.) - gynecological infections (salpingoophoritis, endometritis, inflammatory cysts); - infections present during pregnancy (amnionitis and chorionitis, turbidity of amniotic fluid); - Pyelonephritis during pregnancy; - respiratory tract infections (laryngitis, pharyngitis, tracheitis, pneumonia); - infections of the urinary system (pyelonephritis, cystitis); - bacterial sepsisemia; - gonococcal infections; - Used to prevent infection of surgical operations, as well as to prevent sepsis after abortion and cesarean section. Contraindications: - cases of allergies to ampicillin, sulbactam and other beta-lactam antibiotics; - Infectious mononucleosis, lymphocytic leukemia; - Severe renal and liver failure. Special instructions and precautions: Hypersensitivity reactions may occur during treatment with ampicillin/sulbactam. If an allergic reaction is observed, the use of the drug is stopped, and in such cases antihistamines and corticosteroids are used. Despite the fact that penicillins do not have a toxic effect, during long-term treatment it is necessary to monitor the function of vital organs (kidneys, liver, hemolytic system). interaction with other drugs: The risk of skin reactions increases when taken together with allopurinol. The combined use of ampicillin with aminoglycosides significantly reduces the effect of both drugs. Penicillins enhance the effect of anticoagulants due to their effect on platelet aggregation and hemocoagulation parameters. When used together with oral contraceptives and estrogen-containing drugs, the effectiveness of these drugs is reduced and can lead to unplanned pregnancy. Ampicillin may increase the toxicity of methotrexate by reducing its clearance. Probenecid may reduce the renal clearance of ampicillin and sulbactam, increase ampicillin serum concentrations and increase the risk of intoxication. Use during pregnancy and lactation: Bactocide is used with caution during pregnancy and lactation. The use of the drug is possible only in cases where it is absolutely necessary. Impact on the ability to drive a vehicle and other potentially dangerous mechanisms: Does not affect. Directions for use and dosage: Adults: daily dose ranges from 1.5 g (1 g ampicillin/0.5 g sulbactam) to 12 g (8 g ampicillin/4 g sulbactam). The maximum daily dose of Sulbactam is 4 g. Depending on the severity of the disease, the drug is administered every 6-8 hours. For moderate infections, the drug is used every 12 hours. In renal failure, the excretion of ampicillin and sulbactam is altered, but plasma levels remain unchanged. In such cases, the following scheme is used:   After the temperature normalizes, treatment should be continued for 48 hours. Typically, treatment is carried out for 5-14 days, but in case of severe disease, the treatment period is extended. In order to prevent infection of a surgical operation, 1.5-3 g is administered every 6-8 hours for 24 hours during anesthesia to create a high concentration of the drug in the tissues. If used with an aminoglycoside, the two drugs should be prepared separately and administered to different parts of the body. Children and infants: the daily dose is 150 mg/kg every 6-8 hours; for premature babies and newborns - 150 mg/kg every 12 hours. After dissolution, the drug is injected into the deep muscle layer; the solution should be used within 1 hour after preparation. Bactoside powder is dissolved in a solution of lidocaine hydrochloride for intramuscular injection and in sterile water for intravenous injection. From the gastrointestinal tract: darkening of the upper surface of the tongue, gastritis, diarrhea, enterocolitis, pseudomembranous colitis, nausea, vomiting; From the skin and soft tissues: skin rash, itching, erythema multiforme, urticaria; From the hematopoietic system: agranulocytosis, hematocrit, decrease in the number of erythrocytes, leukocytes or increase in lymphocytes, eosinophils, platelets. These changes are transient, and blood counts return to normal after stopping the drug. According to laboratory indicators: increased activity of ALT and AST, increased LDH, hyperbilirubinemia; Rarely: convulsions, interstitial nephritis. If unexpected effects occur, consult your doctor! Overdose: Because beta-lactam antibiotics accumulate in high concentrations in the cerebrospinal fluid, neurological reactions, including seizures, may occur. Release form: BACTOSID is packaged in a cardboard box with an insert containing

INSTRUCTIONS FOR USE BIOLOGICALLY ACTIVE FOOD SUPPLEMENT BlumActiv® 10 vials of 10 ml For oral use. Not a medicinal product. EACH VIAL CONTAINS: Composition of the dry powder in the vial-container: Active ingredients: Bifidobacterium bifidum Bb-06 – 80.00 mg (live cells not less than: 4×10⁹ CFU), Lactobacillus paracasei Lpc-37 – 15.00 mg (live cells not less than: 3×10⁹ CFU), Lactobacillus acidophilus La-14 – 10.00 mg (live cells not less than: 1×10⁹ CFU), Bifidobacterium breve Bb-18 – 6.67 mg (live cells not less than: 1×10⁹ CFU), Lactobacillus rhamnosus GG – 5.17 mg (live cells not less than: 1×10⁹ CFU), Vitamin B3 as nicotinamide (pure vitamin B3) – 5.40 mg, Vitamin B5 as calcium pantothenate (pure vitamin B5) – 1.80 mg, Vitamin B6 as pyridoxine hydrochloride (pure vitamin B6) – 0.70 mg, Vitamin B2 as riboflavin (pure vitamin B2) – 0.70 mg, Vitamin B1 as thiamine hydrochloride (pure vitamin B1) – 0.42 mg, Vitamin B12 as cyanocobalamin (pure vitamin B12 – 1.25 μg) – 0.13 mg. Composition of the vial: Active ingredients: fructooligosaccharides (pure fructooligosaccharides in the form of powder) – 2000.00 mg – 2150.54 mg, Excipients: fructose, citric acid, raspberry flavoring, potassium sorbate, sodium benzoate, deionized water. Auxiliary substances: silicon dioxide, maltodextrin, magnesium stearate. DAILY DOSAGE PER 1 VIAL: Active ingredients Content per daily dose % of NRV¹ Fructooligosaccharides 2000.00 mg 40%* Vitamin B3 5.40 mg 30% Vitamin B5 1.80 mg 30% Vitamin B6 0.70 mg 35% Vitamin B2 0.70 mg 44% Vitamin B1 0.42 mg 30% Vitamin B12 1.25 μg 125%* ¹ NRV – Recommended daily intake level does not exceed the level according to TR CU 022/2011 “Food Products in Terms of Their Labelling”. Adequate level of daily intake and ** ** Maximum permissible level of daily intake does not exceed according to the Unified Sanitary and Epidemiological and Hygienic Requirements (EAEU), Section 1, Annex 5. DESCRIPTION: BlumActiv® is a combined synbiotic containing 10 billion CFU of lactic acid bacteria and B vitamins, which support the normal functioning of the intestinal microflora. Lactobacilli and bifidobacteria are microorganisms that make up 90% of the normal intestinal microflora. Intestinal microflora is important for the development and complete formation of immunity and normal digestion. Bifidobacteria and lactobacilli protect the body from pathogenic and opportunistic microorganisms and accomplish this in various ways. Bifidobacteria and lactobacteria are protected from the effects of bile acids due to glycolipids contained in their cell walls, forming a protective coating on the intestinal mucosa. B vitamins improve metabolism, promote the growth and reproduction of beneficial microflora. Fructooligosaccharides are prebiotics that promote the growth of beneficial microflora in the intestine. Thus, they support intestinal function and strengthen the immune system. FIELD OF APPLICATION: Recommended as a biologically active food supplement for improving the functional condition of the intestinal microflora and the gastrointestinal tract. RECOMMENDED USE: Adults should take 1 vial once a day. The recommended duration of use is individually determined, from 1 week to 2 months. Press the cap, shake and drink. NUTRITIONAL AND ENERGY VALUE PER 100 ml: Protein – 0.1 g, Fat – 0 g, Carbohydrates – 32.72 g, Energy value – 131.28 kcal / 549.28 kJ. CONTRAINDICATIONS: Individual intolerance to the components of the product. Before use, consultation with a physician is recommended. STORAGE CONDITIONS: Store in a dry place at room temperature, protected from direct sunlight. Keep out of reach of children. SHELF LIFE: 2 years. DOSAGE FORM: In a cardboard package containing 10 vials of 10 ml. MANUFACTURER: «Erbozeta S.p.A.» (Erbozeta S.p.A.) Strada delle Serre, 41/43, 47894, Cezanovo, Republic of San Marino. ORGANIZATION ACCEPTING CLAIMS REGARDING QUALITY IN THE REPUBLIC OF KAZAKHSTAN: Representative Office of CJSC (Closed Joint Stock Company) «Claus Marsh Ltd» in the Republic of Kazakhstan. Almaty, Al-Farabi Ave. 17k, PFC «Nurly-Tau», Block 5B, Office 15. Contacts: +77272480680, info@clausmarsh.com The owner of the trademark and registration certificate is «Claus Marsh», United Kingdom.

INSTRUCTIONS FOR USE BIOLOGICALLY ACTIVE FOOD SUPPLEMENT BlumActiv 7® 20 capsules Not a medicinal product. COMPOSITION: One capsule contains: Active ingredients: Inulin – 113.64 mg Bifidobacterium longum BL21 4×10⁹ CFU – 34 mg Bifidobacterium lactis BLa80 5×10⁹ CFU – 17 mg Bifidobacterium breve BBr60 5×10⁹ CFU – 17 mg Lactobacillus acidophilus LA85 2×10⁹ CFU – 17 mg Lactobacillus paracasei LC86 1×10⁹ CFU – 17 mg Lactobacillus rhamnosus 2×10⁹ CFU – 8.50 mg Bifidobacterium bifidum 1×10⁹ CFU – 3.40 mg Excipients: maltodextrin, magnesium stearate, highly dispersed silicon dioxide. Capsule shell: hydroxypropyl methylcellulose, amidated pectin, glycerin, purified water. DESCRIPTION: BlumActiv 7® is a combined synbiotic containing 20 billion CFU of probiotic lactic acid bacteria and prebiotics that support the balance of intestinal microflora. BlumActiv 7® contains in one capsule the recommended amount of live beneficial lacto- and bifidobacteria and has a unique strain composition of bacteria. All strains work together and enhance each other’s effects. The main probiotics are microorganisms – producers of lactic acid (bifidobacteria and lactobacilli), which are among the most typical representatives of the normal human intestinal microflora. Their combinations are used to restore the intestinal microbiocenosis and maintain good health. Inulin is not digested by the digestive enzymes of the human body and belongs to the group of soluble dietary fibers with a prebiotic effect, stimulating the growth and reproduction of beneficial bacteria in the intestine. FIELD OF APPLICATION: Recommended as a biologically active food supplement for improving the functional condition of intestinal microflora and the gastrointestinal tract. METHOD OF USE: Children aged 6 years and adults should take 1 capsule once a day with food. CONTRAINDICATIONS: Individual intolerance to the components, children under 6 years of age. NUTRITIONAL VALUE PER 100 g: Protein – 11.03 g, Fat – 1.98 g, Carbohydrates – 77.36 g, Energy value – 371 kcal / 1554 kJ. STORAGE CONDITIONS: Store at a temperature of 15–25°C. SHELF LIFE: 36 months. DOSAGE FORM: 20 capsules in a blister. One blister in a cardboard box together with instructions for use in Kazakh and Russian languages. MANUFACTURER: GELPELL AG Address: Kirchbergerstrasse 10, CH-9534 Gähwil, Switzerland. The owner of the trademark and registration certificate is “Claus Marsh”, United Kingdom.  

INSTRUCTIONS FOR USE BIOLOGICALLY ACTIVE FOOD SUPPLEMENT BlumActive® Forte, 10 capsules For oral administration. Not a medicinal product. Composition: Fructooligosaccharides 93% — 100 mg, inulin — 100 mg, gelatin (derived from animal hides) — 98.10 mg, sorbitol — 56.82 mg, Lactobacillus bulgaricus 0.5 × 10⁹ CFU/g, Bifidobacterium longum 4 × 10⁹ CFU/g, Bifidobacterium lactis 4 × 10⁹ CFU/g, silicon dioxide 11 mg, calcium carbonate 10.9 mg, Lactobacillus paracasei 0.5 × 10⁹ CFU/g, Streptococcus thermophilus 1 × 10⁹ CFU/g, Lactobacillus brevis 0.5 × 10⁹ CFU/g, talc 5 mg, fatty acid magnesium salts 4.99 mg, Bifidobacterium bifidum 1 × 10⁹ CFU/g, Lactobacillus helveticus 0.5 × 10⁹ CFU/g, Lactobacillus acidophilus 0.5 × 10⁹ CFU/g, Lactobacillus reuteri 0.5 × 10⁹ CFU/g, Lactobacillus casei 0.5 × 10⁹ CFU/g, Lactobacillus rhamnosus 0.5 × 10⁹ CFU/g, Bifidobacterium breve 5 × 10⁹ CFU/g, Lactobacillus salivarius 0.5 × 10⁹ CFU/g, Lactobacillus plantarum 0.5 × 10⁹ CFU/g. Daily dosage per 1 capsule (520 mg): Composition Per serving % of NRV* Fructooligosaccharides 100 mg 2% Inulin 100 mg 4% Energy value per 100 g: 371.7 kcal / 1555.2 kJ. Nutritional value: protein — 8.2 g, carbohydrates — 25.5 g, dietary fiber — 80.1 g. * NRV — Nutrient Reference Value (according to EC Regulation No. 299 of 28.05.2010, Annex 5). Does not contain GMOs. BlumActive Forte (BlumActive® Forte) is a combined synbiotic consisting of 14 strains, containing 20 billion CFU of probiotic microorganisms, as well as prebiotics that support the balance of intestinal microflora. BlumActive contains a unique combination of live beneficial lacto- and bifidobacteria and has a unique species composition of bacterial strains. All strains work in combination and enhance the action of each other. The composition of BlumActive includes 15 strains of beneficial bacteria, including Streptococcus thermophilus with probiotic properties. Streptococcus thermophilus helps digest and break down lactose (milk sugar) in cases of lactose intolerance, has a beneficial effect, providing a bactericidal effect against pathogenic microorganisms. Lacto- and bifidobacteria are producers of lactic acid and form the basis of the obligate intestinal microflora. They restore the disturbed balance of microflora, ensure its stabilization and increase the number of epithelial cells of the intestine, stimulate the immune functions of the gastrointestinal mucosa. Prebiotics (inulin and fructooligosaccharides) are types of indigestible carbohydrates, known as dietary fiber, which are common natural prebiotics that stimulate the growth and reproduction of beneficial bacteria in the intestine. Indications for use: Recommended as a biologically active food supplement to improve the functional condition of the microflora of the intestine and gastrointestinal tract. Directions for use: Adults: take 1 capsule once daily with meals. The duration of use is determined individually, from 1 week to 2 months. Contraindications: Individual intolerance to the components. Persons under 18 years of age, as well as during pregnancy and breastfeeding, should consult a physician. Precautions: If allergic reactions occur, discontinue use and consult a physician. Form of release: Capsules, 10 capsules in blisters. Storage conditions: Store at room temperature of 15–25°C, in a dry place protected from light, inaccessible to children. Date of manufacture: indicated on the packaging. Shelf life: 2 years. Manufacturer: GRICHAR CHEMICALS r.l., address: via S. Giuseppe No. 18/20, 20861 Brugherio (MB), Italy. Organization accepting quality claims in the Republic of Kazakhstan: Representative office of CJSC (Closed Joint-Stock Company) «Claus Marsh Ltd» in the Republic of Kazakhstan. Almaty, Al-Farabi 17k, Block 5B, Office 15. Contacts: +77272480680, info@clausmarsh.com The owner of the trademark and registration certificate is the company «Claus Marsh», United Kingdom.  

INSTRUCTIONS FOR USE BlumActiv® Immunis 8 vials of 10 ml Biologically active food supplement. Not a medicinal product. For oral use. EACH VIAL CONTAINS: Composition of the cap-vial container: Bifidobacterium breve (Bbr8; B10) + Bifidobacterium animalis lactis (Bi1) (live cells not less than: 5×10⁹ CFU), Lactobacillus paracasei Lpc-37 (live cells not less than: 3×10⁹ CFU), Lactobacillus acidophilus La-14 (live cells not less than: 1×10⁹ CFU), Lactobacillus rhamnosus SP1 (live cells not less than: 1×10⁹ CFU), Vitamin B3 (pure vitamin B3 – 5.40 mg), Vitamin B5 (pure vitamin B5 – 1.80 mg), Vitamin B6 (pure vitamin B6 – 0.70 mg), Vitamin B2 (pure vitamin B2 – 0.70 mg), Vitamin B1 (pure vitamin B1 – 0.42 mg), Vitamin B12 (pure vitamin B12 – 1.25 μg), maltodextrin (filler), anti-caking agents – starch, silicon dioxide, magnesium salts of fatty acids. Composition of the vial: Fructooligosaccharides, deionized water (solvent), fructose (sweetener), citric acid (acidity regulator), natural apricot flavoring, preservatives – potassium sorbate, sodium benzoate. DAILY DOSAGE PER 1 VIAL: Active ingredients Content per daily dose % of NRV* % of UL** Fructooligosaccharides 2000.00 mg — 40 Vitamin B3 5.40 mg 30 — Vitamin B5 1.80 mg 30 — Vitamin B6 0.70 mg 35 — Vitamin B2 0.70 mg 43.75 — Vitamin B1 0.42 mg 30 — Vitamin B12 1.25 μg 125*** — Recommended daily intake level according to TR CU 022/2011 “Food Products in Terms of Their Labelling”. ** Adequate level of daily intake. Unified Sanitary and Epidemiological and Hygienic Requirements (EAEU), Annex 5. DESCRIPTION: BlumActiv® Immunis is a synbiotic complex with an immunomodulatory effect, developed to support the balance of intestinal microflora and strengthen the body’s immune defense. Bifidobacterium animalis has pronounced immunomodulatory properties, helps activate immune cells and maintain the body’s protective functions. Its inclusion in the composition enhances the overall effect on intestinal health and immunity. Lactobacillus rhamnosus SP1 demonstrates a pronounced anti-inflammatory effect, making it an important component in combating chronic inflammatory diseases. It effectively stimulates the activity of immune cells, such as macrophages, and supports antibody production, making it a powerful tool for targeted immune support. Fructooligosaccharides are prebiotics, i.e. food for beneficial bacteria in the intestine. They promote the growth and reproduction of bifidobacteria and lactobacilli. B vitamins improve metabolism and promote the growth and reproduction of beneficial microflora. FIELD OF APPLICATION: Recommended as a biologically active food supplement to support immunity, improve the functional condition of intestinal microflora and the functioning of the gastrointestinal tract. RECOMMENDED USE: Adults should take 1 vial once a day. The recommended duration of use is individually determined, from 1 week to 2 months. METHOD OF USE: Insert the key into the cap and turn it clockwise until it stops. Shake well. Remove the key and unscrew the cap. NUTRITIONAL AND ENERGY VALUE PER 100 ml: Protein – 0.27 g, Fat – 0 g, Carbohydrates – 18.91 g, Energy value – 115 kcal / 479 kJ. CONTRAINDICATIONS: Individual intolerance to the components of the product. Before use, consultation with a physician is recommended. STORAGE CONDITIONS: Store in a dry place at room temperature, protected from direct sunlight. Keep out of reach of children. SHELF LIFE: 2 years. DOSAGE FORM: In a cardboard package containing 8 vials of 10 ml. MANUFACTURER: O.F.I. OFFICINA FARMACEUTICA ITALIANA S.P.A. Via A. Verga, 14, 24127 Bergamo, Italy for “Claus Marsh”, United Kingdom, Regus House, Windmill Hill Business Park, Whitehall Way, Swindon, SN5 6QR. ORGANIZATION ACCEPTING CLAIMS FROM CONSUMERS REGARDING QUALITY IN THE REPUBLIC OF KAZAKHSTAN: Representative Office of CJSC (Closed Joint Stock Company) «Claus Marsh Ltd» in the Republic of Kazakhstan. Almaty, Al-Farabi Ave. 17k, PFC «Nurly-Tau», Block 5B, Office 15. Contacts: +77272480680, info@clausmarsh.com The owner of the trademark and registration certificate is “Claus Marsh”, United Kingdom.  

INSTRUCTIONS FOR USE BlumActiv® Kids 8 vials of 10 ml Biologically active food supplement. Not a medicinal product. For oral use. EACH VIAL CONTAINS: Composition of the dry powder in the vial-container: Folic acid – 200 μg, Vitamin D3 – 5 μg, Bifidobacterium breve (Bbr8; B10) + Bifidobacterium animalis lactis (Bi1) (live cells not less than: 6×10⁹ CFU), L. acidophilus LA-14 (live cells not less than: 1×10⁹ CFU), L. rhamnosus SP1 (live cells not less than: 1×10⁹ CFU), L. reuteri LR-92 (live cells not less than: 1×10⁹ CFU), L. paracasei LPC-37 (live cells not less than: 1×10⁹ CFU), maltodextrin (filler), anti-caking agents – starch, silicon dioxide, magnesium salts of fatty acids. Composition of the liquid in the vial: Fructooligosaccharides (pure fructooligosaccharides in powder form) – 500.00 mg, deionized water (solvent), fructose (sweetener), natural strawberry flavoring, citric acid (acidity regulator). DAILY DOSAGE PER 1 VIAL: Active ingredients Content per daily dose % of NRV* % of UL** Fructooligosaccharides 500.00 mg — 10 Vitamin D3 0.005 mg 100 — Folic acid 0.2 mg 100 — * Recommended daily intake level according to TR CU 022/2011 “Food Products in Terms of Their Labelling”. ** Adequate level of daily intake. Unified Sanitary and Epidemiological and Hygienic Requirements (EAEU), Annex 5. DESCRIPTION: BlumActiv® Kids is a children’s combined synbiotic containing prebiotics, vitamins and probiotic microorganisms that promote the formation of immunity, support digestion and healthy microflora. Fructooligosaccharides are prebiotics that serve as food for beneficial bacteria in the intestine. They promote the growth and reproduction of bifidobacteria and lactobacilli. Vitamin D3: important for the absorption of calcium and phosphorus, bone health and maintenance of immunity. Folic acid: necessary for blood formation, growth and cell development. Bifidobacteria and lactobacilli are key representatives of the intestinal microflora in children. They contribute to the development of immunity, digestion and protection against harmful microorganisms. FIELD OF APPLICATION: Recommended as a biologically active food supplement for improving the functional condition of the intestinal microflora and the gastrointestinal tract. RECOMMENDED USE: Children from 3 years of age: take 1 vial once a day. Recommended duration of use is 8 days. If necessary, the course may be extended up to 16 days on the recommendation of a physician. METHOD OF USE: Insert the key into the cap. Turn it clockwise until it stops. Shake well. Remove the key and unscrew the cap. NUTRITIONAL AND ENERGY VALUE PER 100 ml: Protein – 0.1 g, Fat – 0 g, Carbohydrates – 32.72 g, Energy value – 131.28 kcal / 549.28 kJ. CONTRAINDICATIONS: Individual intolerance to the components of the product. Before use, consultation with a physician is recommended. STORAGE CONDITIONS: Store in a dry place at room temperature, protected from direct sunlight. Keep out of reach of children. SHELF LIFE: 2 years. DOSAGE FORM: In a package containing 8 vials of 10 ml. MANUFACTURER: O.F.I. OFFICINA FARMACEUTICA ITALIANA S.p.A. Via A. Verga, 14, 24127 Bergamo, Italy for «Claus Marsh», United Kingdom, Regus House, Windmill Hill Business Park, Whitehall Way, Swindon, SN5 6QR. ORGANIZATION ACCEPTING CLAIMS REGARDING QUALITY IN THE REPUBLIC OF KAZAKHSTAN: Representative Office of CJSC (Closed Joint Stock Company) «Claus Marsh Ltd» in the Republic of Kazakhstan. Almaty, Al-Farabi Ave. 17k, PFC «Nurly-Tau», Block 5B, Office 15. Contacts: +77272480680, info@clausmarsh.com The owner of the trademark and registration certificate is «Claus Marsh», United Kingdom.  

Instructions for Use CalDesun / Калдесан Biologically Active Food Supplement Composition: Active ingredients: calcium (as calcium carbonate) – 500 mg; magnesium (as magnesium hydroxide) – 150 mg; zinc (as zinc gluconate) – 5 mg; vitamin D3 (cholecalciferol) – 5 μg. Excipients: water, sorbitol, sucrose, xanthan gum, natural flavouring, benzoic acid, sodium cyclamate, acesulfame K*, sucralose, saccharin, polysorbate 80, peppermint oil. * Contains a source of phenylalanine. Recommended use: Recommended as a biologically active food supplement and as an additional source of vitamin D and minerals to support the bones and joints, as well as to help prevent loss of bone mass and bone fractures. Nutritional and energy value per 100 ml: Energy value – 16 kcal / 69 kJ;Fat – 0.4 g;Carbohydrates – 3.3 g;Protein – < 0.1 g. Active ingredient content Name Amount per 10 ml % of AI* per 10 ml Calcium 500 mg 20 Magnesium 150 mg 18.75 Zinc 5 mg 20 Vitamin D3 5 μg 33.3 * AI – Adequate Intake according to the Unified Sanitary and Epidemiological and Hygienic Requirements for Products (Goods) Subject to Sanitary and Epidemiological Supervision (Control). Not a medicinal product. Food supplements do not replace a balanced diet. They must not be used for the treatment of diseases. During pregnancy and lactation, in case of illness or when taking medicinal products, consultation with a physician is required. GMО-free. Directions for use: Take 10 ml up to three times a day. Contraindications: Individual sensitivity to any component of the product. Presentation: Oral solution, 200 ml. Storage conditions: Store at room temperature not exceeding 25°C, in a dry, dark place, out of reach of children. Shelf life: 2 years. Manufacturer: SUNLIFE® Produktions- und Vertriebsgesellschaft mbHSchierbusch 3, 33161 Hövelhof, Germany. Manufactured for:Claus Marsh Ltd., United Kingdom. Organization accepting consumer complaints regarding product quality in the Republic of Kazakhstan: LLP “Altes Pharm” (Altes Pharm)Republic of Kazakhstan, Almaty,83 Tole Bi Street, 7th floor, Office 777. Tel./Fax: +7 701 495 0638

CREAM-GEL FOR EXTERNAL USE Package Leaflet Cosmetic product, not a medicinal product. Composition: Turmeric – 330 mg,Collagen – 500 mg,Chondroitin – 100 mg,Glucosamine – 500 mg,Arnica – 525 mg,Harpagophytum root extract – 525 mg,Rosemary – 175 mg,Tea tree – 213 mg,Camphor – 330 mg. Additional ingredients: Water, propylene glycol, glycerin, sunflower seed oil, denatured alcohol, Ceteareth-20, cetyl alcohol, potassium sorbate, sodium benzoate, menthol, caprylic/capric triglyceride, peppermint oil, glyceryl. Description: Chondrocol Forte is a warming cream-gel with a carefully selected complex of natural ingredients, intended for topical application to the joints and muscles. Due to its high content of turmeric, arnica, camphor and Harpagophytum root extract, the product helps reduce the sensation of pain, muscle tension and discomfort. It provides a gentle warming effect, improves microcirculation and may be used as part of preventive care for disorders of the musculoskeletal system. Suitable for use after physical exertion, exposure to cold, or in cases of chronic joint changes. The cream-gel may be used during physiotherapy procedures, such as phonophoresis, to improve the penetration of active ingredients into the tissues. Areas of application: Prevention of osteochondrosis. For age-related joint changes, as part of preventive care for osteoarthritis of peripheral joints. Prevention of arthritis. For sensations of stiffness and discomfort in the joints. Prevention of synovitis, bursitis, tendovaginitis and myositis as part of comprehensive care for muscle and joint tension. Injuries (dislocations, bruises and sprains) and after physical exertion. Contraindications: Individual sensitivity to any component of the product. Do not use on damaged skin or open wounds. Directions for use: Apply a thin layer to clean, dry skin over the affected joints or muscles 2–3 times a day. Gently massage until completely absorbed. Do not use on damaged skin. May be used in physiotherapy practice, for example, during phonophoresis. Use during pregnancy: The safety of use during pregnancy and lactation has not been established. Use is permitted only after consultation with a healthcare professional. Presentation: Chondrocol Forte cream-gel for external use.100 ml tube. Shelf life: 3 years. Additional information: Store in a dry place at a temperature of +5°C to +25°C, away from heat sources and direct sunlight. Manufactured by order of: “Claus Marsh Ltd”, United KingdomRegus House, Windmill Hill Business Park, Whitehall Way, SN5 6QR, Swindon. Place of manufacture: Via Cosmo Mollica Alagona, 9/11, 95121 – Catania (CT), Italy. Declaration of Conformity Registration Number: ЕАЭС N RU Д-IT.PA08.B.89898/24

Package leaflet Cosmetic product, not a medicinal product. Topical gel based on mineral oils. Structure: Glucosamine Sulfate 1000 mg Chondroitin Sulfate 1000 mg Collagen Hydrolysate 1000 mg Methydsulfonylmethane 500 mg Camphor 2000 mg Additional ingredients: Water, Acrylate/Steareth‑20 Megacrylate Crosspolymer, Propylene Glycol, Carbomer, Glycerin, Pine Oil, Rosemary Oil, Eucalyptus Oil, Citric Acid, Methylchloroisothiazolinone, Methylisothiazolinone. Area of application: Recommended as a cosmetic product for rubbing into the joint area and for skin care. Contraindications: Individual sensitivity to any component of the product. Use during pregnancy: No serious studies on the safe use during pregnancy have been conducted. Method of use and dosage: Apply locally; rub into the affected area 2-3 times a day. The duration of use is 2-3 weeks. Form of release: Chondrocol gel for external use. Tube 100 ml. Shelf life: 3 years. Storage conditions: Store at room temperature not exceeding 25°C in a dry, light‑protected place inaccessible to children. Produced for Claus Marsh LTD, United Kingdom Manufactured by Plantas Medicinales y Complementos Alimenticios, S.A., Av. Prat de la Riba S/N, Antigua Carretera Nacional II, Km. 600, 08780 Palleja, Barcelona, Spain. The organization that accepts consumer complaints regarding quality in the Republic of Kazakhstan: LLP “Altes Pharm”, building 14A, Auezov Street, Almaly District, 050009, Almaty, Kazakhstan.

Compound: Every 3 capsules contain: Glucosamine sulfate 1500 mg; Collagen 800 mg; Methylsulfonylmethane 500 mg; Turmeric extract 400 mg; Chondroitin sulfate 200 mg; Boswellia serrata extract (frankincense tree) 200 mg; Cetyl myristoleate 100 mg. Pharmacological properties: Glucosamine is involved in the construction of cartilage tissue, the formation of tendons, joint fluid, connective tissue of the skin, bones, etc. Glucosamine has a low molecular weight and is almost completely absorbed when taken orally. Thanks to this, it is easy to achieve an effective concentration of glucosamine in cartilage tissue. Glucosamines are also precursors to hyaluronic acid, an important component of synovial fluid. Chondroitin is a specific component of cartilage and is found exclusively in cartilage tissue. CHONDROCOL contains low molecular weight fractions of chondroitin sulfate, which are almost completely absorbed into the gastrointestinal tract and, retaining their structure, are embedded in cartilage tissue. Ondroitin sulfate promotes the retention of water in the thickness of the cartilage in the form of water cavities (microspaces - water cushions), which creates good shock absorption, absorbs shock, and ultimately increases the strength of cartilage tissue and inhibits the action of specific enzymes, including lysosomal ones (elastase, cathepsin, interleukin -1, etc.), released as a result of apoptosis of chondrocytes and destroying cartilage tissue. Chondroitin sulfate, like glucosamine, has an anti-inflammatory and analgesic effect, reducing pain in the joints and spine at rest and when walking. Stabilization of radiological parameters, such as the width of the joint space, indicates a stable restoration of the structure of the articular cartilage, which is not possible to obtain with the use of non-steroidal anti-inflammatory drugs alone. Collagen is a necessary protein for the synthesis of connective and fibrous cartilage tissue. If there is insufficient collagen, cartilage loses its elasticity and strength, becomes rough and fibers. Boswellia serrata (frankincense tree) has a pronounced anti-inflammatory effect, helps strengthen and restore the walls of blood vessels, thereby facilitating blood access to areas of damage, and softens the signs of inflammation in arthritis. The mechanism of action of boswellia, as well as non-steroidal anti-inflammatory drugs (NSAIDs), is based on blocking the synthesis of leukotrienes, but unlike them, it does not cause side effects (ulceration of the mucous membranes, urticaria, bronchospasm, etc.). Methylsulfonylmethane (MSM) is a natural compound of organic sulfur, which is part of sulfur-containing amino acids, complex and simple proteins, enzymes, and other vital biological substrates of the body. MSM improves the permeability of cell membranes, which increases the bioavailability of the main components of the drug into cartilage tissue MSM promotes the regeneration and restoration of the normal structure of connective tissue, including the valve apparatus of the heart, basement membranes of venous and arterial vessels, articular surfaces, tendons, fascia, ligaments of the knee, hip joints, spine and other most vulnerable tissues of the body.

Trade name: Cyclogest® Active ingredient (INN): progesterone Dosage form: pessaries for vaginal and rectal use Compound: Each pessary contains: active substance: progesterone – 200 mg or 400 mg. excipients: solid fatty base. Description: torpedo-shaped pessaries, almost white, about 30 mm long, about 10 mm in diameter. Pharmacotherapeutic group: sex hormones and modulators of the reproductive system. Progestogens. Derivatives of pregnene. Progesterone ATX code: G03DA04 By stimulating protein lipase, it increases fat reserves and increases glucose utilization. By increasing the concentration of basal and stimulated insulin, it promotes the accumulation of glycogen in the liver and increases the production of gonadotropic hormones of the pituitary gland; reduces azotemia, increases nitrogen excretion in urine. Pharmacokinetics Absorption occurs quickly, a high concentration of progesterone is observed 1 hour after administration. Cmax of progesterone in blood plasma is achieved 2-6 hours after administration. When the drug is administered at a dose of 100 mg 2 times a day, the average concentration remains at 9.7 ng/ml for 24 hours. When administered in doses of more than 200 mg/day, the concentration of progesterone corresponds to the first trimester of pregnancy. Plasma protein binding is 90%. Progesterone accumulates in the uterus. Metabolized to form predominantly 3-alpha, 5-beta-pregnanediol. The concentration of 5-beta-pregnanolone in the blood plasma does not increase. It is excreted in the urine in the form of metabolites, the main part being 3-alpha, 5-beta-pregnanediol (pregnandione). This is confirmed by a constant increase in its concentration (Cmax 142 ng/ml after 6 hours). Indications for use Progesterone deficiency conditions in women: -menopausal hormonal therapy in case of progesterone deficiency with non-functioning (absent) ovaries (egg donation); prevention (prevention) of premature birth in women at risk (with shortening of the cervix and/or anamnestic data of premature birth and/or premature rupture of the membranes); -support of the luteal phase during preparation for in vitro fertilization; - support of the luteal phase in the spontaneous or induced menstrual cycle; -premature menopause; -menopausal hormone therapy (in combination with estrogen-containing drugs); - infertility due to luteal insufficiency; - threatened abortion or prevention of habitual abortion due to progesterone deficiency. Directions for use and doses Pessaries are administered intravaginally or rectally at 200 mg to 400 mg twice daily. Prevention (prophylaxis) of preterm birth in women at risk (with shortening of the cervix and/or history of preterm labor and/or premature rupture of membranes): the usual dose is 200 mg at bedtime, from the 22nd to the 34th week pregnancy. Complete absence of progesterone in women with non-functioning (absent) ovaries (egg donation): against the background of estrogen therapy, 100 mg/day on the 13th and 14th days of the cycle, then 100 mg 2 times/day from the 15th to On the 25th day of the cycle, from the 26th day and if pregnancy is detected, the dose increases by 100 mg/day every week, reaching a maximum of 600 mg/day, divided into 3 doses. The indicated dose is usually used for 60 days. Support of the luteal phase during the in vitro fertilization cycle: it is recommended to use from 200 to 600 mg/day, starting from the day of human chorionic gonadotropin injection during the first and second trimesters of pregnancy. Support of the luteal phase in a spontaneous or induced menstrual cycle, in case of infertility associated with dysfunction of the corpus luteum: it is recommended to use 200-300 mg/day, starting from the 17th day of the cycle for 10 days, in case of delayed menstruation and diagnosis of pregnancy, treatment should to be continued. In cases of threatened abortion or in order to prevent habitual abortion occurring against the background of progesterone deficiency: 200-400 mg/day in 2 divided doses daily in the first and second trimesters of pregnancy. Drug interactions The interaction of progesterone with other drugs when administered intravaginally or rectally has not been evaluated. The simultaneous use of other drugs administered intravaginally or rectally should be avoided to avoid interfering with the release and absorption of progesterone. Release form 5 pessaries are placed in contour packages made of polyvinyl chloride/polyethylene film. 3 contour packages together with instructions for medical use in the state and Russian languages ​​are placed in a cardboard pack. Storage conditions Store in original packaging, protected from light at a temperature not exceeding 30 °C. Keep out of the reach of children. Best before date 4 years. Do not take after the expiration date stated on the package. Conditions for dispensing from pharmacies On prescription. Manufacturer Accord-UK Ltd. Barnstaple, EX32 8NS, UK, under license from L.D. Collins & Co. Ltd.” 1st Floor, Gallery Court, 28 Arcadia Avenue, London, N3 2FG, UK.

Demicalcin A combined drug that regulates the metabolism of calcium and phosphorus. Demicalcin mineral and vitamin complex contains a special combination of calcium with vitamin D3, which promotes the absorption of calcium, and with trace elements such as zinc, copper, manganese and boron, necessary for strong bones and spine. Composition: D3 – 50 ME Zn -2 mg Ca citrate - 842 mg Cu -0.5 mg Ca carbonate - 202 mg Mn- 0.5 mg     Ca -250 mg B- 50mcg Pharmacological properties: DeMiCalcin is a mineral and vitamin complex. Replenishes the deficiency of microelements, calcium and vitamin D3, helps strengthen bones and joints, and prevents diseases of the musculoskeletal system. Calcium is a building component for bone tissue. Calcium is presented in the preparation as carbonate and citrate salts Calcium carbonate contains the maximum amount of elemental calcium. Calcium citrate is well absorbed in the intestine, prevents stone formation in the urinary system even with long-term use, and reduces excess production of parathyroid hormone. Vitamin D (cholecalciferol) promotes adequate absorption of calcium, participates in the processes of regeneration and construction of bone tissue. Zinc is an integral component of various enzymes in the body ( more than 200 species) that synthesize proteins and nucleic acids. Manganese promotes the synthesis of substances that are components of bone and cartilage tissue (glycosaminoglycans). Copper is involved in the formation of elastin and collagen. Helps stop the phenomenon of demineralization of bone structures. Boron normalizes the activity of the parathyroid hormone - parathyroid hormone.. Indications: Rickets Prevention and treatment of osteoporosis Period of intensive growth in childhood and adolescence Disorders of calcium metabolism (pregnancy, lactation, convalescence) Prevention of osteoporosis (including menopause) Bone fractures Dosage Up to 1 year – ¼ tablet 1 time per day 1 – 5 years old – ½ tablet once a day 5 – 12 years old – 1 tablet once a day Over 12 years old and adults – 1 tablet 2 times a day Release form: DeMiCalcin, 30 tablets.

Instructions for UseBiologically Active Food SupplementDemicalcin® Advance(Демикальцин® Адванс)Not a medicinal product Composition (per 1300 mg tablet): Aquamin F – powder lithothamnion – 943 mg, microcrystalline cellulose (bulking agent) – 263.8 mg, polyvinylpyrrolidone (agglomerating agent) – 25 mg, magnesium stearate (anti-caking agent) – 20 mg, stearic acid (anti-caking agent) – 15 mg, carboxymethylcellulose (anti-caking agent) – 13 mg, cholecalciferol – 6 mg (including vitamin D3 – 15 μg), spirulina (carrier) – 5 mg, menaquinone – 4.5 mg (including vitamin K2 – 0.035 mg), chlorophyll (carrier) – 4 mg, phylloquinone – 0.7 mg (including vitamin K1 – 0.045 mg). Demicalcin Advance is a tablet consisting of 3 layers. Each layer helps to separate the three individual substances. One layer contains ingredients with immediate release, the second layer provides prolonged release as a maintenance dose. “Fast” layer. 1st phase – release of cholecalciferol 6 mg (including vitamin D3 – 15 μg), K1 and K2.“Medium” layer. 2nd phase – release of Aquamin F lithothamnion powder 600 mg, chlorophyll 4 mg.“Prolonged-release” layer. Aquamin F lithothamnion powder 343 mg. Does not contain GMOs. Daily dosage per 1300 mg tablet: Nutrient % of RDI* Vitamin D3 300** Vitamin K2 29.2 Vitamin K1 37.5 Energy value per 100 g: 227.97 kcal / 953.83 kJNutritional value per 100 g: protein 0.89 g, fat 2.21 g, carbohydrates 51.13 g. * RDI – Recommended Daily Intake (according to TR CU 022/2011, Annex 2).** Does not exceed the upper tolerable intake level (according to EAEU Technical Regulation CU 028.05.2010 No. 299, Section 1, Annex 5). Recommended use: Recommended for adults as a biologically active food supplement containing calcium and potassium and as an additional source of vitamin D3. Helps strengthen bones and joints. Directions for use: Adults: take 1 tablet once a day with a meal. Contraindications: Individual intolerance to the ingredients, pregnancy and lactation, children under 18 years of age. Consult a physician before use. Precautions: If you have allergies, check the product composition. If any adverse reactions occur, discontinue use and consult a physician. Do not exceed the recommended daily dose. Dosage form: 1300 mg tablets in blisters, 3 blisters per carton. Storage conditions: Store at room temperature of 15–25°C, in a dry place protected from light and inaccessible to children. Date of manufacture: See packaging. Shelf life: 3 years. CGF: KZ.16.01.98.003.R.000900.12.24 Manufacturer: FARMIXAL NUTRACEUTICAL MANUFACTURING SERVICES S.R.L.Address: I-95032 Belpasso (CT) – Z.I. Piano Tavola – C.da Pantano SN, Italy. Organization accepting quality complaints in the Republic of Kazakhstan: Representative office of CJSC “Claus Marsh Ltd” in the Republic of Kazakhstan.Almaty, Al-Farabi Ave. 17k, block 5B, office 15.Tel.: +7727480680info@clausmarsh.com The owner of the trademark and registration certificate is “Claus Marsh”, United Kingdom.

  Edenight is an innovative ophthalmic ointment. Composition: 4.5% sodium chloride and 0.4% sodium hyaluronate. Indications: Edenight is a sterile hypertonic ophthalmic ointment indicated for the temporary relief of symptoms of corneal edema such as vision changes and pain, even at night. Due to its high sodium chloride content, Edenight has a higher osmolarity than tear fluid: this difference is necessary for the reabsorption of edematous fluid. The use of Edenight leads to an increase in the concentration of saline in the tear film and, as a result, to the removal of water from the layers of the cornea to the surface. The sodium hyaluronate found in Edenight forms a protective shield on the surface of the cornea, providing protection and hydration. Sodium hyaluronate also makes the application of hypertonic ointment more comfortable due to its lubricating and mechanical protective properties. Recommendations for use: a small amount of ointment is used before bedtime. If an additional daily dose is required, take small portions every 3-4 hours or as directed by a physician. Release form: ophthalmic ointment in a 5 g tube. Manufacturer: Italy.

COMPOUND: Each capsule contains 300 mg of highly purified broccoli indole-3 carbinol, concentrate broccoli cabbage from the cruciferous family 92.5 mg. PHARMACOLOGICAL FEATURES; Evadol is a universal corrector of sexual hyperplastic processes in the organs and tissues of the female reproductive system (breast, endometrium, myometrium, cervix, ovaries). Normalizes the balance of estrogens in the body and suppresses their negative stimulating effects, and also blocks other (hormone-independent) mechanisms that activate pathological cellular growth in the tissues of the mammary gland and uterus. It has the ability to cause selective death of transformed cells with abnormally high proliferative activity. Indole is obtained from plants of the cruciferous family. It belongs to the group of antiestrogenic and antitumor drugs of plant origin. Evadol has an anti-estrogenic effect by restoring normal metabolism of the female sex hormone estradiol and inhibiting the formation of 16-hydroxystrone, which has an oncogenic (promoting the formation of malignant tumors) effect on the woman’s body. At the same time, it suppresses the function of estrogen receptors (nerve endings sensitive to estrogen) in target tissues. This effect of indole allows it to be used for various functional disorders caused by increased levels of estrogen in the blood. Many tumors and pre-tumor diseases of the female genital area and mammary glands have a clear dependence on the amount of estrogens produced in the body. These are mastopathy, breast cancer, uterine fibroids, uterine cancer, endometriosis and so on.   Evadol is able to suppress tissue hyperproliferation (rapid cell proliferation associated with tumor growth) of epithelial origin in the female reproductive system, caused by disturbances in the regulation of cell division. This leads to suppression of the growth of estrogen-dependent tumors of the female reproductive system. At the same time, it promotes the selective destruction (apoptosis) of tumor cells and neutralizes the effect of substances that stimulate the development of mammary tumors. Evadol also exhibits activity against diseases associated with the human papillomavirus (HPV) and suppresses the process of transformation of diseases caused by this virus into malignant tumors, that is, the process of malignancy. The effect of Evadol is enhanced by broccoli concentrate. This allows you to achieve high results after the first course of treatment. Broccoli contains a special substance r::,.;lforaphane, which stops the growth of cancer cells. Another component of broccoli - sinegrin - secretes a substance that stops the division of cancer cells and causes their death. In addition, broccoli is rich in iodine and is an effective preventative against breast cancer. Women who consume this cabbage regularly note not only a decrease in pain in the mammary gland, but also the resorption of small lumps. Also, a rich set of vitamins, such as C, PP, K, U and beta-carotene, helps the body maintain the normal hormone prolactin, which prevents the development of seals and the formation of cysts. INDICATIONS: Evadol is used in combination with traditional treatment methods (including chemotherapy and radiation therapy, surgical methods, immunomodulators, etc.) for diseases of the female reproductive system, the development of which is based on the processes of pathological cell proliferation. Evadol can be used in women for the prevention of hormonal disorders and hormone-dependent diseases, incl. oncological: mastopathy; endometriosis, adenomyosis; myoma (fibroids) of the uterus; ovarian cyst; dysplasia and cervical cancer; premenstrual syndrome; ovarian cancer; mammary cancer. papillomatosis of the female reproductive system, papillomavirus infection (papillomas, genital warts, respiratory papillomatosis), adenomyosis, uterine fibroids and endometrial hyperplasia without atypia, as well as for the prevention of relapses of these diseases after surgical treatment.   CONTRAINDICATIONS: - individual intolerance (including a history of hypersensitivity) to indole-3-carbinol; - not recommended for persons taking medications that reduce the acidity of gastric juice; - strictly contraindicated during pregnancy and lactation. SIDE EFFECTS: Evadol is well tolerated and does not cause side effects at therapeutic doses. USE DURING PREGNANCY AND LACTATION: The drug is strictly contraindicated during pregnancy and lactation! DOSES AND RULES OF APPLICATION: Evadol is prescribed orally before or during meals, 300 mr (1 capsule) daily for 3-6 months. For mastopathy Evado! take 1 capsule 1 time per day for 6 months, for the purpose of prevention – 1 capsule 1 time per day for 3 months.   For endometriosis and uterine fibroids, Evadol is used in complex treatment, 1 capsule once a day for 6 months; in order to prevent relapses, 1 capsule 1 time per day for 3 months. For all forms of human papillomavirus infection, Evadol is used in combination with immunomodulatory or antiviral drugs, 1 capsule once a day for 6 months. STORAGE CONDITIONS: Store at temperatures up to 25°C, in a dry place out of reach of children. RELEASE FORM: Evadol, capsule No. 60. Not a medicine. Dietary supplement CONDITIONS OF DISCHARGE FROM PHARMACIES: Dispensed without a doctor's prescription.

Composition Each capsule contains: Ferrous sulfate — 114 mg (equivalent to elemental iron II) — 35 mg D,L-serine — 129 mg Folic acid — 500 μg Vitamin B12 (cyanocobalamin) — 9 μg Pharmacological properties Iron-replenishing and anti-anemic agent. Iron is a trace element that is part of hemoglobin, myoglobin and certain enzymes. It reversibly binds oxygen, participates in a number of oxidation-reduction reactions and stimulates erythropoiesis. Ferrous sulfate is an optimal form for intestinal iron absorption. The amino acid D,L-serine contributes to more efficient iron absorption and increases iron absorption up to 20-fold. At the same time, iron absorption in the intestine from Ferractin is almost complete. This allows the iron dose to be reduced, providing better tolerability and a significant reduction in the frequency of adverse effects. Folic acid participates in the synthesis of amino acids and nucleic acids, stimulates hematopoiesis, promotes iron absorption and supports lactation. Folic acid is necessary during pregnancy, especially in the third trimester, for healthy fetal development and to reduce the risk of fetal nervous system defects. Vitamin B12 participates in DNA synthesis and is an important factor in growth and hematopoiesis, including the formation and maturation of red blood cells. It is necessary for folate metabolism and the development of the fetal nervous system. Indications Iron-deficiency anemia of various etiologies. Latent iron deficiency associated with excessive iron loss (bleeding, including uterine bleeding; regular blood donation) or increased iron requirements (pregnancy, lactation, periods of active growth, inadequate nutrition, chronic gastritis with secretory insufficiency, conditions following gastric resection, gastric and duodenal ulcer disease, decreased resistance to infectious diseases and tumors in adults and children). Contraindications Hypersensitivity to any component of the product Hemosiderosis Hemolytic anemia Exacerbation of peptic ulcer disease Children under 5 years of age Adverse effects Rarely: a feeling of heaviness in the epigastric region, flatulence, constipation or diarrhea. These effects disappear when the dose is reduced. Dosage and administration Take during meals. The daily dose is determined depending on the patient’s hemoglobin level, body weight and age. Capsules should be taken with a sufficient amount of water. Children aged 5–12 years:1 capsule 1–2 times daily. Adults, pregnant women and children over 12 years: Mild anemia: 1 capsule once daily. Severe anemia: 1 capsule 2–3 times daily. Course of treatment: 2–3 months. Storage conditions Store at room temperature 15–25°C, in a dry place protected from light and out of reach of children. Presentation Plastic bottle containing 30 capsules.One bottle per cardboard box. Available without a doctor’s prescription. Dietary supplement (BAA).Not a medicinal product. Registration State Register of the Republic of Kazakhstan:KZ.16.01.95.003.E.001360.01.17 dated 10 January 2017. The owner of the trademark and registration certificate is Claus Marsh, United Kingdom. Organization accepting complaints in the Republic of Kazakhstan Altes Pharm LLP83 Tolebi Street, Office 777, Almaty, KazakhstanTel.: 8 (727) 292 27 08 Manufacturer Gemini Pharmaceuticals, Inc.87 Modular Avenue, Commack, New York 11725, USA.      

  FORTEGIN Dosage form: vaginal suppositories Composition: One vaginal suppository contains active substances: metronidazole micronized 300.00 mg; miconazole nitrate micronized 100.00 mg; neomycin sulfate 48.80 mg; polymyxin sulfate 4.40 mg; Centella asiatica 15.00 mg. Pharmacotherapeutic group: Combined antimicrobial, antiprotozoal, antifungal and refreshing drug for topical use. ATX code G01AX. Pharmacological properties Metronidazole is a 5-nitroimidazole derivative that has antiprotozoal and antimicrobial effects. The mechanism of action is the biochemical reduction of the 5-nitro group of metronidazole by intracellular transport proteins of anaerobic microorganisms and protozoa. The reduced 5-nitro group of metronidazole interacts with the DNA of microorganisms, inhibiting its synthesis, which leads to the death of bacteria. Active against Trichomonas vaginalis, Entamoeba histolytica, as well as obligate anaerobes Bacteroides spp. (including Bacteroides fragilis, Bacteroides distasonis, Bacteroides ovatus, Bacteroides thetaiotaomicron, Bacteroides vulgatus), Fusobacterium spp., some gram-positive microorganisms (Eubacterium spp., Clostridium spp., Peptococcus niger, Peptostreptococcus spp.). Miconazole nitrate, a derivative of imidazole and triazole, has an antifungal effect: it inhibits the synthesis of ergosterol in the cell membrane. Active against dermatophytes, yeast and some other fungi. Shows antimicrobial activity against gram-positive microorganisms. Does not change the composition of the microflora and pH of the vagina. Neomycin sulfate is a broad-spectrum antibiotic from the aminoglycoside group. Has a bactericidal effect against gram-positive (Staphylococcus spp., Streptococcus pneumoniae) and gram-negative (Escherichia coli, Shigella dysenteria spp., Shigella flexneri spp., Shigella boydii spp., Shigella sonnei spp., Proteus spp.) microorganisms. The mechanism of the bactericidal action of neomycin is associated with the effect on ribosomes and inhibition of protein synthesis in the bacterial cell. Inactive against Streptococcus spp. Resistance of microorganisms to neomycin develops slowly and to a small extent. Polymyxin sulfate is an antibiotic produced by spore-forming bacteria Bacillus polymixa. It has a bactericidal effect associated with disruption of the integrity of the microbial cell membrane. Absorbed on phospholipids of the membrane, increases its permeability, causes lysis of bacteria. Active against gram-negative microorganisms: Pseudomonas aeruginosa, Salmonella spp., Shigella spp., Escherichia coli, Klebsiella spp., Bordetella pertussis, Haemophilus influenzae, Enterobacter. Fusobacteria and bacteroides (Bacteroides fragilis) are moderately sensitive. Does not affect coccal aerobic (Staphylococcus spp., Streptococcus spp., including Streptococcus pneumoniae, Neisseria gonorrhoeae, Neisseria meningitidis) and anaerobic microorganisms, most strains of Proteus spp., Mycobacterium tuberculosis, Corynebacterium diphtheriae and fungi. Centella asiatica has a wound healing effect, stimulates the process of granulation and collagen formation, and promotes epithelization. Indications for use: -vulvitis; -vaginitis; -vulvovaginitis; -cervicovaginitis; -candidiasis; -leukorrhea.   Directions for use and dosage: 1 candle per day, before bedtime. Inserted deep into the vagina in a lying position after evening toilet. Duration of treatment is 5–10 days. Release form Vaginal suppositories. 6 candles are placed in a contour cell packaging made of polyvinyl chloride film. 1 blister pack along with instructions for medical use is placed in a cardboard box. Best before date 3 years. Should not be used after the expiration date. Conditions for dispensing from pharmacies On prescription. Manufacturer: Laboratorios Temis Lostaló S.A. Zepita 3178, C1285ABF, Cuidad Autónoma de Buenos Aires, Argentina.

Glumax is an ophthalmic gel. Composition: dexpanthenol 5%. Indications: Glumax is indicated for maintaining the physiological balance of the ocular surface, providing hydration and protecting the corneal epithelium. Dry eyes due to prolonged use of computer and TV watching, prolonged exposure to heat and air conditioning and provides relief from foreign body sensation, burning, eye strain. Recommendations for use: Glumax when wearing contact lenses - Remove contact lenses before applying the product and wait 15 minutes before reinserting. If used concomitantly with any other ophthalmic products, wait 15 minutes between each use. The product should be used within 8 weeks after first opening the tube. Release form: ophthalmic gel in a tube of 10 g. Manufacturer: Italy.

Solution for intramuscular injection Instructions for use of the medicinal product (for patients) International non-proprietary name: Human Hepatitis B Immunoglobulin Composition Active substance:1 ml of solution contains 100–180 mg of human proteins. The distribution of IgG subclasses is as follows: IgG1 — 63.7% IgG2 — 31.8% IgG3 — 3.3% IgG4 — 1.2% In addition, the maximum amount of IgA is 300 μg/ml. It should be noted that these values represent the proportions and/or concentrations of each subclass in the immunoglobulin product. The immunoglobulin is produced from the plasma of human donors, which is a common source for such products. Excipients: glycine, sodium chloride, water for injections. Description A clear solution ranging from pale yellow to light brown. During storage, the solution may become slightly cloudy and small particles may appear. Pharmacotherapeutic group Immunoglobulins. ATC code: J06BB04. Pharmacological properties IMMUNOHBs is a solution containing human hepatitis B immunoglobulin type B with antibodies against hepatitis B virus. Pharmacodynamics The corresponding section of the supplied source contains corrupted/unreadable text in the extracted document, so I have not reconstructed or supplemented it. The readable part states that IMMUNOHBs demonstrated efficacy. In the study, IMMUNOHBs was administered over a period of 6 months at doses ranging from 2,000 to 2,160 IU every 15 days, depending on the package size. Before each of the 12 administrations, the mean level of measured HBs antibodies exceeded the specified threshold. At a concentration of 180 IU/ml, the mean level was 403 IU/l, while the minimum level was 106 IU/l. Published data on efficacy and safety in the pediatric population did not demonstrate significant differences compared with adults with the same condition. Pharmacokinetics After intramuscular administration, absorption of human hepatitis B immunoglobulin into the bloodstream begins after 2–3 days. The half-life of human hepatitis B immunoglobulin is approximately 3–4 weeks, although individual variations may occur between patients. The breakdown of IgG and IgG complexes takes place in the reticuloendothelial system. Indications for use IMMUNOHBs is used in the following situations: For prevention of recurrent hepatitis B virus infection after liver transplantation associated with liver failure caused by hepatitis B virus. For hepatitis B immunoprophylaxis. In non-immunized individuals who may have been exposed to the virus, including persons whose vaccination is incomplete or whose vaccination status is unknown. In patients undergoing hemodialysis until vaccination becomes effective. In newborns born to mothers who are carriers of hepatitis B virus. In patients who have failed to develop an adequate immune response after vaccination (very low levels of hepatitis B antibodies) and during subsequent prophylaxis when the risk of hepatitis B infection persists. Contraindications Do not use IMMUNOHBs: If you are allergic (hypersensitive) to any component of the product. If you are allergic (hypersensitive) to human immunoglobulins. IMMUNOHBs must not be administered intramuscularly in cases of severe thrombocytopenia or other disorders of hemostasis. IMMUNOHBs must not be administered intravenously. Special warnings and precautions for use Traceability To improve the traceability of biological medicinal products, the name and batch number of the administered product should be clearly recorded. Because of the risk of shock, make sure that IMMUNOHBs does not enter a blood vessel. If the recipient is an HBsAg carrier, administration of this product will not provide any benefit. Hypersensitivity reactions True severe hypersensitivity reactions are rare. IMMUNOHBs contains a small amount of IgA. Individuals with IgA deficiency may develop antibodies against IgA, and anaphylactic reactions may occur following administration of blood components containing IgA. Therefore, when prescribing IMMUNOHBs, the benefits of treatment should be weighed against the potential risk of hypersensitivity reactions. In rare cases, hepatitis B immunoglobulin may cause anaphylactic shock, even in patients who have previously tolerated human immunoglobulin treatment well. If an allergic or anaphylactic reaction is suspected, the injection must be stopped immediately. If shock occurs, standard medical treatment for shock should be administered. Thromboembolism Although thromboembolic events have not been observed, caution should be exercised in patients with pre-existing risk factors. Patients should receive an adequate amount of fluids before receiving immunoglobulins. Particular caution is required in patients with risk factors such as: hypertension; diabetes mellitus; a history of vascular disease or thrombotic episodes; acquired or hereditary thrombophilic disorders; prolonged immobilization; severe hypovolemia; disorders that increase blood viscosity. Patients should be informed about the initial symptoms of thromboembolism, including shortness of breath, pain and swelling of the limbs, focal neurological deficits and chest pain. They should be advised to contact their physician immediately if such symptoms occur. Transmission of infectious agents Standard measures for preventing infections resulting from the use of medicinal products prepared from human blood or plasma include: selection of donors; testing of individual donations and plasma pools for infection markers; effective virus inactivation/removal procedures during manufacturing. Despite these measures, the possibility of transmission of infectious agents cannot be completely excluded when medicinal products prepared from human blood or plasma are administered. These measures are considered effective against enveloped viruses such as HIV, HBV and HCV, as well as non-enveloped viruses such as HAV. The measures may have limited effectiveness against non-enveloped viruses such as parvovirus B19. Clinical experience regarding the unsuccessful transmission of hepatitis A virus and parvovirus B19 through immunoglobulins has been accumulated, and it is also recognized that the antibody content itself contributes positively to viral safety. It is strongly recommended that whenever IMMUNOHBs is administered to a patient, the product name and batch number should be recorded to maintain a link between the patient and the commercial batch of the product. Important information about some ingredients of IMMUNOHBs Each 1 ml of this medicinal product contains 3.9 mg of sodium. A 3 ml vial contains up to 11.7 mg of sodium, corresponding to approximately 0.19% and 0.58% of the maximum daily sodium intake of 2 g recommended by the WHO for adults, according to the source text. Interaction with serological tests Following immunoglobulin injection, the levels of various antibodies passively transferred with human blood may temporarily increase. This may lead to false-positive results in serological tests. Passively transferred antibodies against erythrocyte

00 micrograms (1500 IU) solution for intramuscular injection International Nonproprietary Name: Human anti-D immunoglobulin Composition Active substance:Each pre-filled syringe containing 2 ml of solution contains 300 micrograms (1500 IU) of human anti-D immunoglobulin. It is prepared from the blood plasma of human donors. Excipients: glycine, sodium chloride, water for injections. Description A clear, colourless, pale yellow or light brown solution. During storage, slight cloudiness or a small amount of sediment may appear. Pharmacotherapeutic group Anti-D (Rh) immunoglobulin ATC code: J06BB01. Pharmacological properties IMMUNORHO is a solution of human anti-D immunoglobulin containing antibodies that act against the D-type Rhesus factor. The D-type Rhesus factor is a specific characteristic of human blood cells. People who carry the D-type Rhesus factor are Rh(D)-positive, while those who do not carry it are Rh(D)-negative. When an Rh(D)-negative person receives Rh(D)-positive blood—for example, when the blood of an Rh(D)-negative pregnant woman comes into contact with the blood of an Rh(D)-positive fetus—the mother’s immune system recognizes the Rh(D)-positive fetal erythrocytes as foreign blood cells and produces specific antibodies against the D-type Rhesus factor. This process, known as immunization, usually takes 2–3 weeks. Therefore, Rh(D)-positive blood cells are not destroyed during the first exposure and no signs or symptoms usually occur. Upon subsequent exposure to Rh(D)-positive blood, the antibodies previously produced are ready to destroy the Rh(D)-positive fetal erythrocytes. This may cause hemolytic disease of the newborn. When human anti-D (Rh) immunoglobulin is administered to an Rh(D)-negative person, it prevents the formation of antibodies against Rh(D)-positive erythrocytes. Immunization against the D-type Rhesus factor can be prevented in more than 99% of cases. To achieve this, treatment with IMMUNORHO should be started with an adequate dose before the first exposure to Rh(D)-positive erythrocytes or as soon as possible after exposure. The mechanism by which anti-D immunoglobulin prevents immunization against Rh(D)-positive erythrocytes is not known. It may be related to the removal of erythrocytes from the circulation before they reach the relevant sites. Other, more complex mechanisms involving antigen recognition and antigen presentation by appropriate cells, with or without the participation of antibodies, may also be involved. Pharmacokinetic properties After intramuscular administration, anti-D immunoglobulin is slowly absorbed and reaches the circulation after a delay of approximately 2–3 days. The half-life of human anti-D immunoglobulin is approximately 3–4 weeks, although this may vary from patient to patient. IgG and IgG complexes are broken down in cells of the reticuloendothelial system. Indications for use IMMUNORHO is used to prevent Rh(D) immunization in Rh(D)-negative women of reproductive age in the following situations: Antenatal prophylaxis Routine antenatal prophylaxis. Antenatal prophylaxis following pregnancy complications, including: abortion/threatened abortion; ectopic pregnancy; hydatidiform mole; antepartum hemorrhage resulting from transplacental bleeding; amniocentesis; chorionic biopsy; obstetric procedures, such as external version; invasive procedures; fetal blood sampling from the umbilical cord (cordocentesis); acute abdominal trauma; therapeutic procedures involving the fetus in utero. Postnatal prophylaxis Following delivery of an Rh(D)-positive infant (D, weak D, partial D). IMMUNORHO is also indicated in Rh(D)-negative women of reproductive age following inappropriate transfusion of Rh(D)-positive blood or other products containing erythrocytes, such as platelet concentrates. Contraindications Hypersensitivity to human immunoglobulin or to any of the other components of this medicinal product. Hypersensitivity to human immunoglobulins, particularly in patients with antibodies against IgA. Special warnings and precautions for use Consult your doctor or nurse before using IMMUNORHO. Due to the risk of shock, care must be taken to ensure that IMMUNORHO is not administered intravenously. For postnatal use, the product is intended for administration to the mother. It must not be administered to the newborn infant. The product is not intended for use in Rh(D)-positive individuals. Hypersensitivity True hypersensitivity reactions are rare, but allergic reactions to anti-D immunoglobulin may occur. IMMUNORHO contains a small amount of IgA. Although human anti-D immunoglobulin has been successfully used in some individuals with IgA deficiency, individuals with IgA deficiency may develop anti-IgA antibodies and may experience anaphylactic reactions following administration of medicinal products derived from plasma containing IgA. Therefore, the physician should carefully assess the benefits of treatment with IMMUNORHO against the potential risk of hypersensitivity reactions. In rare cases, human anti-D immunoglobulin may cause an anaphylactic reaction accompanied by a decrease in blood pressure, even in patients who have previously tolerated treatment with human immunoglobulin. If an allergic or anaphylactic reaction is suspected, the injection must be stopped immediately. The physician will discontinue administration and treat the reaction according to its nature and severity. Hemolytic reactions If very high doses of anti-D immunoglobulin are administered following an inappropriate blood transfusion, a hemolytic reaction may occur. For this reason, your doctor will monitor you closely and determine whether specific blood tests are necessary. Thromboembolism Arterial and venous thromboembolic events, including myocardial infarction, stroke, deep vein thrombosis and pulmonary embolism, have been associated with the use of immunoglobulins. Although thromboembolic events have not been observed in patients receiving IMMUNORHO, patients should receive adequate fluids before administration of immunoglobulins. Particular attention should be paid to patients with pre-existing risk factors for thrombotic events, including: hypertension; diabetes mellitus; vascular disease or a history of thrombotic events; hereditary or acquired thrombophilia; prolonged immobilization; severe hypovolemia; diseases associated with increased blood viscosity; particularly patients receiving high doses of IMMUNORHO. Patients should be informed about the initial symptoms of thromboembolic events, including shortness of breath, swelling and pain in the limbs, focal neurological deficits and chest pain, and should be advised to contact their doctor immediately if these symptoms occur. The appropriate dose should be calculated in consultation with a specialist in transfusion medicine. Viral safety Standard measures should be taken to prevent infections resulting from the use of medicinal products prepared from human blood or plasma. These include: careful selection of blood and plasma donors to exclude donors at risk of carrying infections; screening of each donor and additional donors for signs of viral/infectious diseases; inclusion of virus inactivation/removal steps during the processing of blood or plasma. Despite these measures, the possibility of transmission of infection cannot be completely excluded when medicinal products prepared from

Inestom International nonproprietary name Levocarnitine Dosage form Oral solution, 1 g/10 ml Compound 1 ml of the drug contains active substance - levocarnitine 100.0 mg, Excipients: malic acid, methylparaben (E 218), propylparaben (E 216), sodium saccharin dihydrate, orange flavor, purified water.   Description Transparent solution from colorless to yellowish. Pharmacotherapeutic group Other drugs for the treatment of gastrointestinal diseases and metabolic disorders. Amino acids and their derivatives. Levocarnitine. ATX code A16AA01   Pharmacological properties Pharmacokinetics After ingestion, levocarnitine (L-carnitine), as a result of the action of intestinal flora, is metabolized into trimethylamine (TMA) and γ-butyrobetaine. Approximately 10-20% of levocarnitine reaches the systemic circulation unchanged. Therefore, it is believed that intestinal metabolism is responsible for the elimination of 80-90% of an orally administered dose. Both metabolites, TMA and γ-butyrobetaine, are absorbed in the small intestine. γ-butyrobetaine is excreted unchanged in urine, while TMA is metabolized in the liver to trimethylamine-N-oxide (TMAO) and is found in urine, mainly as TMAO, with small amounts as unchanged TMA. In cases of hemocatharsis (blood purification), end-stage renal failure or chronic use of levocarnitine, the amount of TMA and TMAO in the blood increases and, as a consequence, the amount of TMA in the urine increases. Levocarnitine, after absorption through the intestines, reaches its maximum concentration in the blood after 3 hours. High levels of levocarnitine are maintained in the blood plasma for 9 hours. Excreted by the kidneys, more than 80% of the dose taken remains unchanged within 24 hours. Levocarnitine can be found in muscles and organ parenchyma. Pharmacodynamics Levocarnitine is present as a natural component in the tissues of animals, microorganisms and plants. In the human body, the requirements for normal metabolism are met through the consumption of foods containing carnitine, as well as through endogenous synthesis in the liver and kidneys from lysine and methionine, which are donors of the methyl group. Only the L-isomer of carnitine (levocarnitine) is biologically active and plays a major role in lipid metabolism, In the metabolism of ketone bodies, as a link in the amino acid chain. Levocarnitine is involved in the transport of long-chain fatty acids in mitochondria (promotes the oxidation of fatty acids), that is, it participates as a carrier of fatty acids across cell membranes from the cytoplasm to the mitochondria, where it undergoes the process of beta-oxidation with the formation of a large amount of metabolic energy in the form of ATP. Левокарнитин улучшает работу цикла Кребса (путем освобождения СоА, действия СоА, при участии фермента  карнитин-ацилтрансферазы),  стимулирует активность пируват дегидрогеназы в скелетных мышцах и окисление разветвленных звеньев цепи аминокислот. Таким образом, левокарнитин прямо или косвенно включается в различные процессы обмена веществ и является важным фактором не только окисления жирных кислот и кетоновых тел, но также глюкозы и некоторых аминокислот.   Indications for use - primary and secondary levocarnitine deficiency in adults and children over 12 years of age Directions for use and doses The drug is taken orally, the solution can be drunk without dilution or diluted in 100 ml of chilled boiled water or fruit juice. To determine the optimal dose, it is recommended to monitor therapy by measuring the levels of free and acyl levocarnitine in blood plasma and urine. The level of free levocarnitine in the blood plasma should be 35 - 60 mol/l. The ratio of acyl levocarnitine to the level of free levocarnitine in blood plasma should not be higher than 0.35. Adults and children over 12 years old Primary and   secondary levocarnitine deficiency: recommended doses Inestomas depend on the metabolic disorder and the severity during the treatment period. In most cases, the recommended oral dose is 100-200 mg/kg/day in 2-4 divided doses. If clinical and biochemical parameters do not improve, the dose may be increased for a short time. High doses up to 400 mg/kg/day may be necessary for acute metabolic decompensation In case of secondary carnitine deficiency in patients with end-stage chronic renal failure receiving hemodialysis: if significant clinical improvement was achieved after the first course of intravenous use of Inest, maintenance therapy with Inest, oral solution, is prescribed at a dose of 1 g/day.   Side effects Side effects are not observed when using Inest, as prescribed by the doctor. Rarely - nausea, vomiting, abdominal pain, diarrhea Reducing the dose leads to elimination of side effects. - muscle weakness, cramps in patients with uremia - allergic reactions (skin itching, skin rash, urticaria, Quincke's edema, anaphylactic shock) - specific body odor - increase in INR (International Normalized Ratio) when used together with coumarins (acenocoumarol or warfarin) Contraindications - hypersensitivity to the components of the drug - children's age up to 12 years Drug interactions Prescribing Inestoma to patients with diabetes mellitus receiving insulin or oral hypoglycemic drugs may cause hypoglycemia due to increased glucose absorption. Therefore, in this category of patients, during treatment with Inest, the level of glucose in the blood plasma should be constantly monitored to correct the dosage regimen of hypoglycemic drugs. Glucocorticosteroids contribute to the accumulation of the drug in tissues (except the liver). Lipoic acid and anabolic steroids enhance the effect of levocarnitine. There have been very rare reports of increased INR in patients receiving coumarin anticoagulants together with levocarnitine. Patients receiving such anticoagulants concomitantly with levocarnitine should have their INR or other appropriate coagulation test monitored weekly until stabilized and monthly thereafter. If you use any other medications together with Inestom, you must inform your doctor about this. Special instructions Inestome is not addictive or addictive because it is a natural component of the body. Tolerance to the drug should be monitored during the first week of treatment and after each dose increase. Ingestion of high doses of Inestoma is not recommended for patients with severely impaired renal function or those on dialysis in end-stage renal disease, this may lead to the accumulation of potentially toxic metabolites trimethylamine (TMA) and trimethyl-N-oxide (TMAO), which are usually excreted in the urine . This can cause a "fishy odor" in urine, breath and sweat. This situation is not observed after intravenous administration

  K-Elixir 30 ml (drops) A herbal complex of extracts of goldenrod, asparagus, juniper and buchu leaves for the treatment and prevention of inflammatory diseases of the kidneys and urinary tract. K-Elixir has antibacterial and anti-inflammatory, antispasmodic and mild diuretic effects on the genitourinary tract. Ingredients:  Goldenrod extract – 9 mg, Asparagus (asparagus) extract – 9 mg, Buchu leaf extract – 9 mg, Juniper leaf extract – 3 mg Pharmacological features: A combined herbal medicine that has a complex effect on the functions of the kidneys and urinary tract: uroseptic, urospasmolytic, anti-inflammatory, litholytic and diuretic Canadian goldenrod extract – exhibits antibacterial, antispasmodic, anti-inflammatory, litholytic and diuretic properties. The litholytic effect is manifested by normalizing water-salt metabolism and acid-base balance. The extract is especially active against uraturia and oxalaturia, and to a lesser extent against phosphaturia. Reduces the amount of nitrogen in the blood and changes the pH of urine. The bacteriostatic effect is most pronounced against gram-positive bacteria of the genus Staphylococcus, Streptococcus, Enterococcus. The extract potentiates the effect of antibiotics when used together. Anti-inflammatory, diuretic and antispasmodic effects are manifested due to the presence of flavonoids, saponins and alkaloids. By improving blood microcirculation in the tissues of the prostate gland, it has a prostatotropic effect. Asparagus racemosus extract (asparagus) - Has diuretic and anti-inflammatory effects. Without changing the filtration capacity of the renal glomeruli, it significantly reduces the reabsorption function of the convoluted tubules of the kidneys Buchu leaf extract - has a mild diuretic, antiseptic and anti-inflammatory effect. The pyogenic properties are associated with the content of flavonoids in the leaves, and the antiseptic properties are associated with diosphenol. Juniper leaf extract - has a diuretic effect on edema, which is associated with the presence of essential oil and terpineol contained in it, which enhances filtration in the renal glomeruli and inhibits the reverse resorption of sodium and chlorine ions in the convoluted tubules of the kidneys. Has a phosphatolytic effect. Indications: Mono-/complex therapy, maintenance and anti-relapse therapy of chronic inflammatory diseases of the kidneys and urinary tract: pyelonephritis, cystitis, urethritis Prevention and complex treatment, anti-relapse therapy of urolithiasis (uraturia, oxalaturia, phosphaturia), including after operations to remove stones. Treatment and prevention of urinary tract infections (bacteriuria, cystitis, pyelonephritis) during pregnancy, prevention and complex therapy of gestosis Complex therapy of kidney diseases in diabetes mellitus Complex treatment and prevention of nephritis in children. Polycystic kidney disease Complex treatment of chronic prostatitis Contraindications:  Individual intolerance to the components of the drug. Dosage: 1-3 years - 5 drops 2 times a day in a small volume of water 3 g–6 years – 5 drops 2-3 times a day in a small volume of water 6-12 years – 5-7 drops – 2-3 times a day in a small volume of water 12 years and older – 5-10 drops 2-3 times a day in a small volume of water Depending on the severity of the condition, the dose can be increased to 10-15 drops 3-4 times a day in a small volume of water. Take between meals for 7-10 days. Release form: bottle, drops 30 ml Manufacturer: Alpha Laboratories Inc. Miami - Florida.

Complex lymphatic drainage preparation. L-elexir stimulates metabolism, improves lymphatic drainage from tissues, increases the barrier functions of lymph nodes, and enhances the elimination of toxic substances from the intercellular environment. L-Elixir Compound: 1 ml of solution contains: Ceanothus americana extract…………………… 9 mg Red clover flowers extract…………………. 7.5 mg Stillingia root extract………………………… 7.5 mg Zanthoxylum American extract……………….. 6 mg   Pharmachologic effect: L-elixir has decongestant, lymphatic drainage, immunomodulatory, detoxification and anti-inflammatory effects. L-elixir stimulates metabolism, improves lymphatic drainage of tissues, increases the barrier functions of lymph nodes, and enhances the elimination of toxic substances from the intercellular environment. As a result, the interaction between cells of the endocrine, immune and nervous systems improves. Also, by activating the intestinal lymphatic system, L-elixir creates the prerequisites for strengthening local immunity, both of the intestinal mucosa and the mucous membranes of other organs. Under the influence of L-elixira, the delivery of other drugs to the affected areas is accelerated, which makes it possible to reduce the doses of drugs taken and reduce the toxic effect of drugs on the body. Indications: -Lymphadenopathy, chronic tonsillitis, tonsil hypertrophy, mesoadenitis; -Thimomegaly (complex treatment); -Various infectious intoxications (tuberculous, tonsillogenic, and others); -Exudative-catarrhal, lymphatic-hypoplastic diathesis; -Diseases accompanied by immunodeficiency; -Drug intoxication; -Diabetes mellitus with the occurrence of polyneuropathy; - Perineural edema; -Lymphatism (including elephantiasis); -Lymphatic edema (post-traumatic, post-mastectomy, post-operative); -Dysbiosis; -Renal, cardiac edema;   Dosage and method of application: Newborns and children under 2 years old - 3-5 drops 2-3 times a day, Children from 2 to 6 years old - 7-8 drops 2-3 times a day. Children over 6 years old and adults – 10 drops 2-3 times a day. L-elixir is taken sublingually. The drug can be dissolved in 5-10 ml of ordinary water (1-2 teaspoons). Take half an hour before meals, or 50-60 minutes after meals. The daily dose of the drug prescribed by the doctor can be diluted in 250 ml of water and drunk in small sips throughout the day (the liquid must be retained in the mouth). Contraindications: Individual hypersensitivity to the components of the drug. When using the drug in During pregnancy and lactation, consultation with a doctor is necessary. Side effects: There are no reports of side effects at this time. Interaction with other drugs: L-elixir is combined with other medications. Overdose: To date, no data on overdose symptoms have been reported. Release form: L-elixir, drops for oral administration, 30 ml. Not a medicine. Dietary supplement Conditions for dispensing from pharmacies: Dispensed without a doctor's prescription. Storage conditions: Store tightly packaged in a cool place, out of reach of children.   Manufactured for Claus Marsh, UK Manufactured by CJ Labs, Inc., USA

Instructions for Use Biologically active food supplementL-epilife® Forte (L-эпиликсиф® Форте) Not a medicinal product Composition of the hermetically sealed dosing cap Fraxinus excelsior L. folium (European ash leaf) — 20 mg, including chlorogenic acid — 0.40 mg Echinacea purpurea (L.) Moench radix (echinacea root) — 20 mg Trifolium pratense L. herba (red clover herb) — 15 mg, including isoflavones — 1.20 mg Glycyrrhiza glabra L. radix (licorice root) — 15 mg, including glycyrrhizic acid — 0.30 mg Arctium lappa L. radix (burdock root) — 15 mg Composition of the bottle Fructose — 2300 mg (sweetener) Lemon flavor — 30 mg (sweetener, flavoring agent) Potassium sorbate — 10 mg (preservative) Sodium benzoate — 10 mg (preservative) Benzoic acid — 10 mg (preservative) Demineralized water — up to 10 ml (solvent) Contains a sweetener. Excessive consumption may cause a laxative effect. GMO-free. Daily intake per 10 ml Component % of adequate daily intake* Chlorogenic acid 0.8% Isoflavones 2.4% Glycyrrhizic acid 3% Nutritional value (per 100 ml): 35.4 kcal / 148.1 kJProtein — 1.07 g; fat — 0.8 g; carbohydrates — 5.98 g. *ADI — adequate daily intake according to the EU Commission Regulation dated 28.05.2010 No. 299, Section 1, Annex 5. Application Recommended for adults as a source of flavonoids, flavonolignans and arbutin. The unique form with a hermetically sealed dosing cap preserves the stability of the dry mixture until activation, ensuring precise dosing and maximum effectiveness of the components. L-epilife® is developed on the basis of a complex of plant-based ingredients with pronounced physiological activity. It supports activation of lymphatic drainage and immune function and participates in metabolic processes involved in the regulation of endocrine, immune and nervous functions. Regular use helps improve microcirculation and lymph flow. It supports normal tissue condition in case of a tendency toward fluid retention and provides a mild antiseptic effect, contributing to the body’s natural protective mechanisms. Directions for use Adults: 1 bottle once daily, during or between meals. Before use: press the cap, shake well and drink. Contraindications Individual intolerance to the components, pregnancy and lactation, children under 18 years of age. Consult a doctor before use. Do not exceed the recommended daily dose. Precautions In case of allergies, check the composition of the product. If adverse reactions occur, discontinue use and consult a doctor. Presentation Hermetically sealed bottle containing 10 ml of dry mixture in the dosing cap. Packed in a cardboard box containing 7 bottles, with instructions in Russian and Kazakh. Storage conditions Store at room temperature 15–25°C, in a dry place protected from light and out of reach of children. Date of manufacture: see packaging.Shelf life: 3 years. SGR: KZ.16.01.96.003.R.000478.05.25 Manufactured by order of “Claus Marsh Ltd”, United KingdomRegus House, Windmill Hill Business Park, Whitehall Way, Swindon, SN5 6QR. Manufacturer ERBOZETA S.P.A.Strada delle Seriole, 41/43 — Loc. GalavottoZona Ind. Gualdicciolo, 47893 Chiesanuova (R.S.M.), Republic of San Marino. Organization accepting quality complaints in the Republic of Kazakhstan Representative Office of “Claus Marsh Ltd” in the Republic of Kazakhstan:Almaty, Al-Farabi St. 17K, PFC “Nurly-Tau”, Block 5B, Office 15. Contacts: +7 727 480 6080Email: info@clausmarsh.com Trademark and Registration Certificate Holder “Claus Marsh Ltd”, United Kingdom.

Lucarnit is a sterile ophthalmic solution. Composition: L-carnitine 0.25%, sodium hyaluronate 0.7%. Indications: Lucarnit - designed to provide long-term eye protection thanks to the combination of a high concentration of sodium hyaluronate and levocarnit. Lucarnit - thanks to the gel composition of the condensed formula, long-term irritation caused by external factors such as wind, sun, dry air, salt water, smoke, excessive lighting, heating, air conditioning; dry eye syndrome; eliminates foreign body and burning sensation in the eyes. Long-term use of a computer and tablet, post-ocular surgery; It is successfully used for eye discomfort due to prolonged, frequent wearing of contact lenses. Recommendations for use: Instill 1-2 drops into the affected eye 3-4 times a day, lightly pressing on the body of the bottle. Once the liquid has reached less than half of the bottle, apply a little more pressure to the body of the bottle to release the drop. Please note that excessive pressure may cause the solution to flow out in a stream rather than a trickle. Release form: sterile ophthalmic solution in a 10 ml bottle. Manufacturer: Italy

Ursoflor International nonproprietary name Ursodeoxycholic acid Dosage form Gelatin capsules 300 mg Compound One tablet contains active substance – ursodeoxycholic acid 300.00 mg, excipients: corn starch, anhydrous colloidal silicon dioxide, magnesium stearate, gelatin capsule composition: titanium dioxide (E171), iron oxide (III) yellow (E172), gelatin.   Description Hard gelatin capsules with a white body and a yellow cap, size No. 0, the contents of the capsules are white powder. Pharmacotherapeutic group Preparations for the treatment of diseases of the biliary tract. Bile acid preparations. Ursodeoxycholic acid. ATX code A05AA02   Pharmacological properties Pharmacokinetics After oral administration, ursodeoxycholic acid is rapidly absorbed in the small intestine and the beginning of the ileum by passive transport and at the end of the ileum by active transport. The absorption rate is typically 60-80%. After absorption, bile acid undergoes almost complete conjugation in the liver with the amino acids taurine and glycine, and is then excreted in the bile. The first clearance through the liver reaches 60%.   Depending on the daily dose and the existing liver disorder or condition, more and more hydrophilic ursodeoxycholic acid accumulates in the bile. At the same time, there is a relative decrease in the content of other, more lipophilic bile acids. Under the influence of intestinal bacteria, the drug is partially broken down into 7-keto-lithocholic acid and lithocholic acid. Lithocholic acid is hepatotoxic and can cause parenchymal liver lesions in some animal species. In humans, a very small amount is absorbed, which is sulfated in the liver and thus detoxified before being excreted in the bile or ultimately in the feces. The biological half-life of ursodeoxycholic acid is 3.5-5.8 days. Pharmacodynamics Ursoflor - a hepatoprotector has a choleretic effect. Reduces cholesterol synthesis in the liver, its absorption in the intestines and concentration in bile, increases the solubility of cholesterol in the biliary system, stimulates the formation and excretion of bile. Possessing high polar properties, UDCA forms non-toxic mixed micelles with apolar (toxic) bile acids, which reduces the ability of gastric reflux to damage cell membranes. In addition, UDCA forms double molecules that can be incorporated into cell membranes, stabilize them and make them immune to the action of cytotoxic micelles. Reduces the saturation of bile with cholesterol by inhibiting its absorption in the intestine, suppressing synthesis in the liver and reducing secretion into bile; increases the solubility of cholesterol in bile, forming liquid crystals with them; reduces the lithogenic index of bile. The result is the dissolution of cholesterol gallstones and the prevention of the formation of new stones. In addition, UDCA forms double molecules that can be incorporated into cell membranes, stabilize them and make them immune to the action of cytotoxic micelles. Reduces the saturation of bile with cholesterol by inhibiting its absorption in the intestine, suppressing synthesis in the liver and reducing secretion into bile; increases the solubility of cholesterol in bile, forming liquid crystals with them; reduces the lithogenic index of bile. The result is the dissolution of cholesterol gallstones and the prevention of the formation of new stones   Indications for use - treatment of primary biliary cirrhosis - dissolution of radiolucent gallstones in the gallbladder Directions for use and doses The dosage regimen and duration of treatment with Ursoflor are determined individually, depending on the severity of the disease. Ursoflor capsules are taken orally with food, without chewing, with a sufficient amount of water. Dissolution of cholesterol gallstones – всю суточную дозу принимают 1 раз перед сном в дозе от 10 мг/кг массы тела до 15 мг/кг (2-5 капсул). Длительность процесса растворения желчных камней при применении препарата составляет от 6 месяцев до 2 лет. Если через 6 месяцев не наблюдается уменьшения размеров желчных камней, прием препарата считается нецелесообразным. После полного растворения камней прием продолжают в суточной дозе 600 мг (2 капсулы) 1 раз в день перед сном еще 3 месяца (для профилактики рецидивов). Первичный билиарный цирроз – рекомендуемая доза 300 мг 2 раза в сутки (с учетом 14 + 2 мг/кг) в течение 3 месяцев. Дозировки для лечения пациентов педиатрического возраста не просматривались.   Side effects Common (≥1/100, but <1/10 people) - pasty stool - diarrhea Very rare (< 1/10ˈ000 people) - severe pain in the abdominal area, on the right side, during treatment of primary biliary cirrhosis - calcification of gallstones - decompensation of liver cirrhosis, in the treatment of late stages of primary biliary cirrhosis, which partially regresses after discontinuation of the drug. - urticaria Contraindications - acute inflammatory diseases of the gallbladder or bile ducts, empyema of the gallbladder - obstruction of the bile ducts (common bile ducts or cystic ducts) - frequent episodes of hepatic colic - X-ray positive (high calcium) gallstones - disorders of gallbladder contractility - hypersensitivity to the components of the drug or bile acids - children with biliary atresia: unsuccessful portoenterostomy, normal bile flow is not restored - children and adolescents up to 18 years of age.   Drug interactions Cholestyramine, cholestipol and antacids containing aluminum hydroxide or smectite (aluminum oxide) reduce the absorption of ursodeoxycholic acid in the intestine and thus reduce its absorption and effectiveness. If the use of drugs containing at least one of these substances is still necessary, they should be taken at least 2 hours before or after taking Ursoflor. Ursodeoxycholic acid may affect the absorption of cyclosporine from the intestine. Therefore, in patients taking cyclosporine, the physician should check the concentration of cyclosporine in the blood and adjust the dose of cyclosporine if necessary. In a clinical study in healthy volunteers, concomitant use of ursodeoxycholic acid (500 mg/day) and rosuvastatin (20 mg/day) resulted in slightly elevated plasma levels of rosuvastatin. The clinical significance of this interaction with other statins is unknown. In some cases, Ursoflor may reduce the absorption of ciprofloxacin. Ursodeoxycholic acid has been shown to reduce peak plasma concentrations (Cmax) and the area under the pharmacokinetic curve (AUC) of the calcium antagonist nitrendipine in healthy volunteers. Careful monitoring of the results of simultaneous use of nitrendipine and ursodeoxycholic acid is recommended. An increase in the

Vitamin C Ingredients: 20 effervescent tablets with orange flavor with Vitamin C, 1000 mg each. Additional Ingredients: Citric Acid, Ascorbic Acid, Acidity Regulator (Sodium Bicarbonate), Bulking Agent (Sorbitol), Polyethylene Glycol, Maltodextrin, Sweeteners (Aspartame, Acesulfame K), Gum, Natural Orange Flavor, Color (Riboflavin), Lime Flavor. Indications: as a dietary supplement as an additional source of Vitamin C. Dose of use: adults are recommended to take 500 mg/day, children aged 14 years and older 250 mg/day. Directions for use: dissolve one effervescent tablet in 200 ml of boiled, cooled water, adults take ½ glass per day, children aged 14 years and older take ¼ glass per day. Do not exceed the indicated daily allowance. Should not be used as a substitute for various diets or healthy lifestyles. Keep out of the reach of children! Store at temperatures between 15°C and 25°C. Storage conditions: it is recommended to store dissolved vitamins in the refrigerator at a temperature from +2° to +4C°, closed, for no more than 18-24 hours. Warnings: Close the cap tightly after use and store in a cool, dry place. Before first use, check that the protective cover is intact. Excessive consumption may cause a laxative effect. Shelf life – 2 years. The expiration date and batch number are indicated on the bottom of the tube. Manufacturer: Innopharma s.r.o.Mliečany 105 / Owner of the trademark and certificate registration is the company "Claus Marsh", Great Britain.

Composition Each tablet contains: Calcium (calcium A.A.C.) — 100 mg, 11% Magnesium (magnesium A.A.C.) — 100 mg, 24% Inositol — 100 mg L-carnitine — 75 mg Taurine — 100 mg Glycine — 75 mg Niacinamide — 75 mg, 375% Zinc — 15 mg Vitamin B6 (pyridoxine hydrochloride) — 3 mg, 750% Pantothenic acid (calcium pantothenate) — 20 mg Vitamin B5 — 3 mg, 750% Choline — 15 mg Vitamin B1 (thiamine hydrochloride) — 3 mg, 750% Vitamin B2 (riboflavin) — 3 mg, 750% Folic acid — 200 μg Vitamin B12 (cyanocobalamin) — 3 μg Daily requirement has not been established. Other ingredients: stearic acid, cross-linked sodium carboxymethyl cellulose, silicon dioxide, magnesium stearate. Pharmacological properties A combination product with a pronounced tonic effect, accelerates carbohydrate and fat metabolism. Taurine improves metabolic processes, promotes oxygen uptake and exchange in the brain, improves oxygen utilization and reduces the need for oxygen in the myocardium, increases the body’s resistance to hypoxia, improves mental performance, memory and concentration, and has a beneficial effect on the cardiovascular system and skeletal muscles. Valerian, passionflower and hop extracts have sedative properties, reduce excitability, irritability, anxiety and emotional tension, and normalize sleep. B vitamins: thiamine, riboflavin, nicotinamide, folic acid, niacin and inositol normalize metabolism in the nervous system and have a metabolic effect, as well as contributing to the normal functioning of the immune system and the nervous system. Calcium and magnesium ions regulate impulse transmission between nerve cells and muscle contractions. Rutin improves microcirculation. In conditions of oxygen deficiency, they increase the body’s resistance to hypoxia. Indications Memory, attention and thinking disorders Decreased intellectual abilities Psychological and physical asthenia Method of administration and dosage Adults and children over 12 years: take 1 tablet in the morning and 1 tablet during the day, 1–3 hours before meals. Children under 12 years: according to the doctor’s prescription. Take for the recommended duration of treatment. Contraindications Hypersensitivity to any component of the product. Adverse effects In cases of individual intolerance to certain components of the product, allergic reactions may occur. Special instructions Do not take before bedtime. When used concomitantly with antidepressants, take under medical supervision. Pharmaceutical form Vitason, tablets No. 30. Available without a doctor’s prescription. Dietary supplement (BAA).Not a medicinal product. Storage conditions Store at room temperature 15–25°C, in a dry place protected from light and out of reach of children. Manufacturer Gemini Pharmaceuticals, Inc.87 Modular Avenue, Commack, New York 11725, USA. The owner of the trademark and registration certificate is Claus Marsh, United Kingdom. Organization accepting complaints in the Republic of Kazakhstan:Altes Pharm LLP, Almaty, Tolebi St. 83, Office 777.Tel.: 8 (727) 292 27 08 State Register of the Republic of Kazakhstan:KZ.16.01.95.003.E.001362.01.17 dated 10.01.2017.

Instructions for Use Biologically Active Food SupplementVitason® Duo(Витасон® Дуо)Not a medicinal product Composition (per 1300 mg tablet): Microcrystalline cellulose – 253.5 mg, calcium carbonate – 250 mg (including calcium – 100 mg), magnesium oxide – 167 mg (including magnesium – 100 mg), dry extract of Ginkgo biloba leaves – 120 mg (including ginkgoflavonoids – 30 mg), L-taurine – 100 mg, inositol – 100 mg, L-glycine – 75 mg, niacin – 60 mg, dry extract of the aerial parts of Passiflora incarnata – 30 mg (including vitexin – 1.05 mg), polyvinylpyrrolidone – 30 mg, dry extract of Valeriana officinalis – 30 mg (including valerenic acid – 0.126 mg), magnesium stearate – 20 mg, silicon dioxide – 15 mg, vitamin B5 – 15 mg, dry extract of common hop inflorescences – 15 mg (including flavonoids – 0.015 mg), sodium carboxymethylcellulose – 13 mg, yellow iron oxide – 3.5 mg (colouring agent), vitamin B6 – 3 mg. Vitason® Duo tablets consist of 2 layers. One layer contains ingredients with immediate release, while the second layer provides prolonged release. “Fast” layer.Phase 1 – release of components with a sedative effect that have a beneficial effect on sleep (valerian, passionflower, hops). “Prolonged-release” layer.Phase 2 – release of components after 8 hours (taurine, Ginkgo biloba, glycine), which help maintain alertness in the morning and improve performance. Does not contain GMOs. Recommended daily intake per 1300 mg tablet: Component % of RDI* % of AI** Calcium 10 Valerenic acid 25 Magnesium 333.3*** Flavonoids 250*** L-Taurine 150*** Inositol 6.3 L-Glycine 12.006 Niacin 25 Vitexin 20 Vitamin B5 2.1 Vitamin B6 10.5 Energy value per 100 g: 269.53 kcal / 1127.71 kJ Nutritional value per 100 g: protein – 1.13 g, fat – 0.45 g, carbohydrates – 65.24 g. * RDI – Recommended Daily Intake (according to TR CU 022/2011, Annex 2). ** AI – Adequate Intake (according to the Unified Sanitary and Epidemiological and Hygienic Requirements approved by the Decision of the Customs Union Commission No. 299 dated 28 May 2010, Section 1, Annex 5). *** Does not exceed the upper tolerable intake level (according to the Unified Sanitary and Epidemiological and Hygienic Requirements approved by the Decision of the Customs Union Commission No. 299 dated 28 May 2010, Section 1, Annex 5). Recommended use: Recommended for adults as a biologically active food supplement. Used as an additional source of calcium, magnesium, valerenic acid, ginkgoflavonoids, vitexin and flavonoids of common hop. Helps improve memory, attention and cognitive function. Directions for use: Adults: take 1 tablet once daily with breakfast. Contraindications: Individual intolerance to the components, pregnancy and lactation, children under 18 years of age. Consult a physician before use. Precautions: If you have allergies, check the product composition. In case of adverse reactions, discontinue use and consult a physician. Do not exceed the recommended daily dose. Dosage form: 1300 mg tablets in blisters, 30 tablets per carton. Storage conditions: Store at room temperature 15–25°C, in a dry place protected from light and inaccessible to children. Date of manufacture: See packaging.Shelf life: 3 years. SGR: KZ.16.01.98.003.R.000713.10.24 Manufacturer: FARMAXIAL NUTRACEUTICAL MANUFACTURING SERVICES S.R.L.Address: I-95032 BELPASSO (CT) – Z.I. PIANO TAVOLA – C.DA PANTANO SN, Italy. Organization accepting quality complaints in the Republic of Kazakhstan: Representative Office of CJSC “Claus Marsh Ltd” in the Republic of Kazakhstan.Almaty, Al-Farabi Ave. 17K, Block 5B, Office 15.Tel.: +7 727 248 0680info@clausmarsh.com The owner of the trademark and registration certificate is “Claus Marsh”, United Kingdom.

Biologically Active Food Supplement 30 capsulesNot a medicinal product Composition Each capsule contains: Active ingredients: Betaine hydrochloride — 150 mg (7.5%) Inulin — 50 mg (2%) α-Amylase (100,000 units) — 48 mg Papain powder — 30 mg Pectin powder E440 — 30 mg (1.5%) Chicory root powder — 20 mg Dry fennel root extract — 15 mg Dry turmeric root extract — 15 mg Dry milk thistle leaf extract — 10 mg Cellulase (25 units) — 9.80 mg Lactase (100,000 units) — 8.0 mg Dry Fucus vesiculosus thallus extract — 7 mg Dry wakame seaweed extract — 4 mg Liquid wakame seaweed extract Nori — 4 mg Lactobacillus acidophilus 100 billion CFU/g (KОЕ 1×10¹⁰) — 2 mg Protease (750 units/g) — 1.60 mg Lactobacillus Rhamnosus (KОЕ 3×10⁹) — 1.5 mg Lipase (30 units/g) — 1.34 mg Bifidobacterium longum (KОЕ 1×10⁹) — 1 mg Bifidobacterium breve (KОЕ 1×10⁹) — 1 mg Lactobacillus casei (KОЕ 1×10⁹) — 1 mg Bifidobacterium bifidum (KОЕ 1×10⁹) — 1 mg Lactobacillus salivarius (KОЕ 5×10⁸) — 0.5 mg Lactobacillus plantarum (KОЕ 5×10⁸) — 0.5 mg Excipients: Hard white vegetable capsule (hypromellose, vegetable cellulose, maltodextrin, silicon dioxide E551), magnesium stearate. Does not exceed the established acceptable daily intake level according to EU Regulation, Chapter 7, Annex 5. Description VITAZIM® ADVANCE is a complex of digestive enzymes that supports improved digestion and more efficient absorption of nutrients. The composition contains the enzymes lactase, cellulase, amylase, protease and lipase, each of which performs a specific function: they participate in the breakdown of corresponding nutrients and ensure their further absorption by the body. The product additionally contains a complex of bifidobacteria and lactobacilli, which supports the normal balance of intestinal microflora and contributes to healthy gastrointestinal function. Protease participates in the breakdown of dietary proteins into amino acids, improves their absorption and supports complete digestion. Amylase is an enzyme that breaks down complex carbohydrates into oligosaccharides, which are subsequently converted into glucose. It participates in the digestion of carbohydrates for absorption. Lipase is an enzyme responsible for breaking down dietary fats into fatty acids and glycerin, facilitating their absorption in the intestine. Pectin is a dietary fiber of plant origin that helps normalize intestinal function, supports the balance of microflora and improves the absorption of nutrients. Cellulase is an enzyme that promotes the breakdown of plant fibers and supports digestion. Betaine hydrochloride is a lipotropic substance that promotes increased acidity of gastric juice, improves protein digestion and absorption, and participates in liver metabolism. Papain is a plant-derived proteolytic enzyme that breaks down proteins into peptides and amino acids, facilitating their digestion and absorption. It may be beneficial in metabolic disorders, including fatty liver disease. Chicory root powder is a plant-based ingredient with antispasmodic and stimulating properties that supports normal gastrointestinal motility and improves the absorption of nutrients. Bifido- and lactobacteria are probiotic microorganisms that support the normal balance of intestinal microflora, contributing to improved digestion and immune function. Wakame seaweed extract is a source of iodine and probiotics that supports the growth of beneficial bacteria in the intestine and helps maintain healthy microflora. Area of application Recommended as a biologically active food supplement containing a combination of highly active enzymes that improve digestion and promote more efficient absorption of nutrients. Directions for use Adults: take 1 capsule during main meals, 3 times a day. Nutritional and energy value per 100 g: Protein — 17.08 g Fat — 2.84 g Carbohydrates — 74.94 g Energy value — 394 kcal / 1648 kJ Contraindications Hypersensitivity to the components Jaundice Intestinal obstruction Children under 18 years of age Storage conditions Store at room temperature 15–25°C, in a dry place protected from light and out of reach of children. Shelf life 2 years. Pharmaceutical form 15 capsules in one blister.Two blisters are packed in a cardboard box together with instructions for use. Manufacturer FARMAXIAL NUTRACEUTICAL MANUFACTURING SERVICES S.R.L. – Z.I. PIANO TAVOLA – C.DA PANTANO SN, I-95032 BELPASSO (CT), Italy,for “Claus Marsh”, United Kingdom, Regus House, Windmill Hill Business Park, Whitehall Way, Swindon, SN5 6QR. Organization accepting quality complaints in the Republic of Kazakhstan Representative Office of “Claus Marsh Ltd” in the Republic of Kazakhstan: Almaty, Nauryzbay Batyr Street, Building 382, Office 2.Tel.: +7 (727) 240 86 80Email: info@clausmarsh.com Trademark and Registration Certificate Holder “Claus Marsh”, United Kingdom. MTK/SGR No.: KZ.16.01.98.003.R.000916.11.25

VITAZIM pills Compound: Each tablet contains: Pancreatin 200 mg, *; Protease enzyme 100 mg, *; Amylase enzyme 100 mg, *; Betaine hydrochloride 100 mg, *; Calcium (phosphate) 50 mg; Pepsin 1: 10,000 50 mg, *; Bromelain 1: 10-80 GDU 50 mg, *; Papain 50 mg, *; Ox bile 30 mg, *; Lipase enzyme 25 mg, *; Cellulase enzyme 10 mg, *. *Daily requirement has not been established. Other Ingredients: Cellulose, stearic acid, croscarmellose sodium, silicon dioxide, magnesium stearate. This product DOES NOT CONTAIN: citrus fruits, grains, eggs, dairy, soy, yeast, sugar additives, starch, synthetic dyes, artificial flavorings, gluten, sodium and preservatives. Pharmacological features: A multi-enzyme drug, which is a combination of highly active enzymes of animal and plant origin, as well as a hepatoprotector. Pepsin is one of the main proteolytic enzymes of the digestive tract. Pepsin breaks down proteins and stimulates the production of gastrin and cholecystokinin, which is an important link in the coordination of the regulation of digestion. Ox bile – enhances the production of bile and pancreatic juice, has a choleretic effect, promotes the digestion of fats and promotes the secretion of pancreatic lipase. Protease – participates in the breakdown of proteins. Amylase is involved in the breakdown of starch. Lipase, together with bile acids, breaks down food triglycerides into fatty acids and participates in the breakdown and absorption of fats. Cellulase is not synthesized by the human digestive system; it digests plant fibers (fiber) to form glucose and disaccharides. In addition, cellulase releases soluble fiber to bind cholesterol and toxins in the digestive tract. Bromelain is a proteolytic enzyme obtained from pineapple fruits and leaves; Its action is similar to that of pepsin and trypsin. Increases the activity of other enzymes, promotes the breakdown of protein foods and their absorption by the body. Bromelain also has the ability to break down fats, which is important in regulating fat metabolism. Papain is a proteolytic enzyme of plant origin, similar to the action of bromelain and used to improve digestion. Betaine hydrochloride is a lipotropic substance of plant origin. Activates lipid metabolism in the liver, normalizes the level of triglycerides in the blood, and participates in metabolic processes. It has a bile-forming and choleretic effect, normalizes the acidity of gastric contents. It is a hepatoprotector, helps prevent fatty liver degeneration and reduce blood cholesterol. Indications: Digestive disorders due to dietary errors (taking “heavy” fatty foods, diet, irregular meals, overeating), belching, nausea, heartburn, heaviness after eating, unpleasant taste in the mouth, flatulence. Directions for use and dosage: Adults and children over 12 years of age: 1 tablet with main meals 3 times a day. Use before the stated expiration date. Contraindications: Jaundice, intestinal obstruction, hypersensitivity to the components of the drug. Side effects: In case of individual intolerance to individual components of the drug, allergic reactions and diarrhea are possible. Storage conditions: Store at room temperature 15-250C, in a dry place, protected from light, out of reach of children. Not a medicine. Dietary supplement Dispensed without a doctor's prescription. Release form: Vitazim, tablets No. 30, in a bottle. Manufacturer: Gemini Pharmaceutical Inc., 87 Modular ave., Commack, NY 11725, USA. The owner of the trademark and certificate of registration is Claus Marsh, UK. Organization accepting claims in the Republic of Kazakhstan: Altes Pharm LLP, Almaty, st. Tolebi, 83, office 777. Tel: 8 (727) 292 27 08. SoGR KZ.16.01.97.003.E.000654.06.16 dated 06/23/2016